PhaseÂ I/II study of COVID-19 RNA vaccine BNT162b1 i

Nature

586, 589-593

DOI: 10.1038/s41586-020-2639-4

Citation Report

#	Article	IF	Citations
1	Challenges in the Development of a Vaccine Against COVID-19. Engineering, 2020, 6, 1067-1069.	3.2	0
2	Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. Frontiers in Microbiology, 2020, 11, 583252.	1.5	18
3	Coronavirus disease-19 vaccine development utilizing promising technology. Current Opinion in HIV and AIDS, 2020, 15, 351-358.	1.5	4
4	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 2020, 586, 594-599.	13.7	1,520
5	The Coronavirus Disease 2019 pandemic: how does it spread and how do we stop it?. Current Opinion in HIV and AIDS, 2020, 15, 328-335.	1.5	7
6	A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 2020, 5, 237.	7.1	427
7	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet, The, 2020, 396, 1595-1606.	6.3	511
8	SARS-CoV-2 vaccines in development. Nature, 2020, 586, 516-527.	13.7	1,659
9	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	13.9	2,107
10	Profile of SARS-CoV-2. Wiener Klinische Wochenschrift, 2020, 132, 635-644.	1.0	4
11	The immunology of SARS-CoV-2 infections and vaccines. Seminars in Immunology, 2020, 50, 101422.	2.7	85
12	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity, 2020, 53, 1281-1295.e5.	6.6	285
14	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy, 2020, 5, 282.	7.1	149
15	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nature Communications, 2020, 11, 4059.	5.8	266
16	Vaccines against COVID-19. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 703-705.	0.6	31
17	The Current Status of COVID-19 Vaccines. Frontiers in Genome Editing, 2020, 2, 579297.	2.7	25
18	Emerging Concepts and Technologies in Vaccine Development. Frontiers in Immunology, 2020, 11, 583077.	2.2	159
19	An Effective COVID-19 Vaccine Needs to Engage T Cells. Frontiers in Immunology, 2020, 11, 581807.	2.2	75

#	Article	IF	Citations
20	Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. Journal of Experimental Medicine, 2020, 217, .	4.2	55
21	What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist. Frontiers in Immunology, 2020, 11, 2173.	2.2	8
22	Phase 1â€“2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine, 2020, 383, 2320-2332.	13.9	1,000
23	Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology, 2020, 20, 615-632.	10.6	806
24	Vaccines targeting SARS-CoV-2 tested in humans. Nature Medicine, 2020, 26, 1336-1338.	15.2	7
25	Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Interferon and Cytokine Research, 2020, 40, 543-548.	0.5	31
26	Development of vaccines and antivirals for combating viral pandemics. Nature Biomedical Engineering, 2020, 4, 1128-1133.	11.6	66
27	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. Clinical Infectious Diseases, 2020, 73, 1540-1544.	2.9	15
28	Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Science, 2020, 27, 104.	2.6	287
29	A Potential Peptide From Soy Cheese Produced Using Lactobacillus delbrueckii WS4 for Effective Inhibition of SARS-CoV-2 Main Protease and S1 Glycoprotein. Frontiers in Molecular Biosciences, 2020, 7, 601753.	1.6	39
30	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Frontiers in Immunology, 2020, 11, 569760.	2.2	30
31	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Frontiers in Immunology, 2020, 11, 571481.	2.2	48
32	Flu RNA Vaccine: A Game Changer?. Vaccines, 2020, 8, 760.	2.1	2
33	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. Vaccines, 2020, 8, 746.	2.1	6
34	Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science Immunology, 2020, 5, .	5.6	404
35	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. Journal of Biological Chemistry, 2021, 296, 100025.	1.6	43
36	Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology, 2021, 19, 211-219.	13.6	126
37	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	1.0	88

#	Article	IF	Citations
38	New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine, 2021, 39, 197-201.	1.7	67
39	Spike mutation D614G alters SARS-CoV-2 fitness. Nature, 2021, 592, 116-121.	13.7	1,380
40	SARS-CoV-2: Targeted managements and vaccine development. Cytokine and Growth Factor Reviews, 2021, 58, 16-29.	3.2	44
41	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomedicine and Pharmacotherapy, 2021, 133, 111008.	2.5	40
42	Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines. Advanced Functional Materials, 2021, 31, 2008352.	7.8	25
43	COVID-19: A review of therapeutic strategies and vaccine candidates. Clinical Immunology, 2021, 222, 108634.	1.4	180
44	COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. International Immunopharmacology, 2021, 90, 107247.	1.7	87
45	COVID-19 vaccine race: watch your step for cancer patients. British Journal of Cancer, 2021, 124, 860-861.	2.9	31
46	COVID-19: The Effect of Host Genetic Variations on Hostâ€“Virus Interactions. Journal of Proteome Research, 2021, 20, 139-153.	1.8	14
47	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. SLAS Discovery, 2021, 26, 311-329.	1.4	4
48	Viral targets for vaccines against COVID-19. Nature Reviews Immunology, 2021, 21, 73-82.	10.6	832
49	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine, 2021, 31, 100689.	3.2	206
50	Non-viral COVID-19 vaccine delivery systems. Advanced Drug Delivery Reviews, 2021, 169, 137-151.	6.6	152
51	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	15.2	473
52	COVID-19. Critical Care Nursing Quarterly, 2021, 44, 128-137.	0.4	17
53	Hybridization Networks of mRNA and Branched RNA Hybrids. ChemBioChem, 2021, 22, 924-930.	1.3	2
54	Informed consent disclosure to vaccine trial subjects of risk of COVIDâ€19 vaccines worsening clinical disease. International Journal of Clinical Practice, 2021, 75, e13795.	0.8	21
55	Is there a role for childhood vaccination against COVIDâ€19?. Pediatric Allergy and Immunology, 2021, 32, 9-16.	1.1	38

#	Article	IF	Citations
56	Repurposed Drugs, Molecular Vaccines, Immuneâ€Modulators, and Nanotherapeutics to Treat and Prevent COVIDâ€19 Associated with SARSâ€CoVâ€2, a Deadly Nanovector. Advanced Therapeutics, 2021, 4, 2000172.	1.6	24
57	Deciphering Vaccines for COVID-19: where do we stand today?. Immunopharmacology and Immunotoxicology, 2021, 43, 8-21.	1.1	13
58	Structural Insights into the Interaction of Clinically Relevant Phosphorothioate mRNA Cap Analogs with Translation Initiation Factor 4E Reveal Stabilization via Electrostatic Thio-Effect. ACS Chemical Biology, 2021, 16, 334-343.	1.6	16
59	Promising COVID-19 Vaccines. SpringerBriefs in Applied Sciences and Technology, 2021, , 115-126.	0.2	0
60	Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination. Journal of Korean Medical Science, 2021, 36, e158.	1.1	11
61	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. Emerging Microbes and Infections, 2021, 10, 1589-1597.	3.0	41
62	Application of Nanotechnology in the COVID-19 Pandemic. International Journal of Nanomedicine, 2021, Volume 16, 623-649.	3.3	60
63	Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action. Current Topics in Microbiology and Immunology, 2021, , 1.	0.7	9
64	Engineering SARS-CoV-2 using a reverse genetic system. Nature Protocols, 2021, 16, 1761-1784.	5.5	137
65	COVID-19-neutralizing antibodies predict disease severity and survival. Cell, 2021, 184, 476-488.e11.	13.5	586
66	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerging Microbes and Infections, 2021, 10, 342-355.	3.0	37
67	The role and uses of antibodies in COVID-19 infections: a living review. Oxford Open Immunology, 2021, 2, iqab003.	1.2	17
68	An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 2021, 9, 97.	2.1	117
69	RNA-Based COVID-19 Vaccine Candidates with Clinical Phase Trials in Progress. Turkish Journal of Medical Sciences, 2021, , .	0.4	0
70	COVID-19: Characteristics and Therapeutics. Cells, 2021, 10, 206.	1.8	177
71	COVID-19 and Malignancy: Exploration of the possible genetic and epigenetic interlinks and overview of the vaccination scenario. Cancer Treatment and Research Communications, 2021, 28, 100425.	0.7	1
72	Immunological Changes in Pregnancy and Its Relation to COVID-19 Infection. , 2021, , 23-37.		0
73	The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines. Immunotherapy Advances, 2021, 1, ltab019.	1.2	4

#	Article	IF	Citations
74	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. ACS Central Science, 2021, 7, 183-199.	5.3	134
75	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	2.6	167
76	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110214.	0.7	29
77	Evaluation of the safety and efficacy of using human menstrual bloodâ€derived mesenchymal stromal cells in treating severe and critically ill COVIDâ€19 patients: An exploratory clinical trial. Clinical and Translational Medicine, 2021, 11, e297.	1.7	90
78	Antibodies to neutralising epitopes synergistically block the interaction of the receptorâ€binding domain of SARSâ€CoVâ€2 to ACE 2. Clinical and Translational Immunology, 2021, 10, e1260.	1.7	13
80	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. Annual Review of Microbiology, 2021, 75, 19-47.	2.9	52
81	Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines. Brazilian Journal of Medical and Biological Research, 2021, 54, e10725.	0.7	9
82	Potential of Immune-Related Therapy in COVID-19. Frontiers in Pharmacology, 2020, 11, 609212.	1.6	3
83	The Worldwide Effort to Develop Vaccines for COVID-19. Advances in Experimental Medicine and Biology, 2021, 1327, 215-223.	0.8	3
84	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1
85	Declined Antibody Responses to COVID-19 mRNA Vaccine within First Three Months. SSRN Electronic Journal, 0, , .	0.4	2
86	A Trans-Complementation System for SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	1
88	Management of COVID-19 Infection During Pregnancy, Labor, and Puerperium. , 2021, , 63-89.		1
89	Interaction of serum proteins with SARS-CoV-2 RBD. Nanoscale, 2021, 13, 12865-12873.	2.8	14
90	The Techniques Used on the Development of COVID-19 Vaccine. E3S Web of Conferences, 2021, 271, 01037.	0.2	0
91	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nature Structural and Molecular Biology, 2021, 28, 202-209.	3.6	110
92	Disposable photonics for cost-effective clinical bioassays: application to COVID-19 antibody testing. Lab on A Chip, 2021, 21, 2913-2921.	3.1	20
93	mRNA vaccines for COVID-19: what, why and how. International Journal of Biological Sciences, 2021, 17, 1446-1460.	2.6	185

#	Article	IF	Citations
94	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. Vaccines, 2021, 9, 36.	2.1	41
95	Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. Vaccines, 2021, 9, 61.	2.1	105
96	Virus-associated ribozymes and nano carriers against COVID-19. Artificial Cells, Nanomedicine and Biotechnology, 2021, 49, 204-218.	1.9	5
98	Tick-Tattoo: DNA Vaccination Against B. burgdorferi or Ixodes scapularis Tick Proteins. Frontiers in Immunology, 2021, 12, 615011.	2.2	12
99	COVID-19 basics and vaccine development with a Canadian perspective. Canadian Journal of Microbiology, 2021, 67, 112-118.	0.8	3
101	Instrumental analysis of RNA modifications. Critical Reviews in Biochemistry and Molecular Biology, 2021, 56, 178-204.	2.3	26
102	Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. Vaccine, 2021, 39, 1310-1318.	1.7	113
103	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nature Communications, 2021, 12, 776.	5.8	65
104	The race to a COVID-19 vaccine: opportunities and challenges in development and distribution. Drugs in Context, 2021, 10, 1-10.	1.0	77
105	Next-generation COVID-19 vaccines: here come the proteins. Lancet, The, 2021, 397, 643-645.	6.3	9
106	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. JMIR Public Health and Surveillance, 2021, 7, e22483.	1.2	2
108	A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biology, 2021, 19, e3001091.	2.6	163
109	Omics-Driven Biotechnology for Industrial Applications. Frontiers in Bioengineering and Biotechnology, 2021, 9, 613307.	2.0	49
110	Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nature Human Behaviour, 2021, 5, 337-348.	6.2	1,002
111	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. Annual Review of Pharmacology and Toxicology, 2022, 62, 25-53.	4.2	20
113	Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet, The, 2021, 397, 682-694.	6.3	235
115	A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2. Protein Journal, 2021, 40, 260-295.	0.7	24
116	Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. Cell, 2021, 184, 881-898.	13.5	56

#	Article	IF	Citations
118	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Frontiers in Immunology, 2021, 12, 631139.	2.2	117
119	COVID-19 mRNA vaccines. Journal of Genetics and Genomics, 2021, 48, 107-114.	1.7	59
120	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines, 2021, 9, 147.	2.1	175
121	The challenge of avidity determination in SARSâ€CoVâ€2 serology. Journal of Medical Virology, 2021, 93, 3092-3104.	2.5	32
122	mRNA vaccine: a potential therapeutic strategy. Molecular Cancer, 2021, 20, 33.	7.9	188
123	Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19. Saudi Pharmaceutical Journal, 2021, 29, 173-187.	1.2	23
124	Harnessing biomaterials for therapeutic strategies against COVID-19. Emergent Materials, 2021, 4, 9-18.	3.2	9
125	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 2021, 592, 283-289.	13.7	494
126	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature Communications, 2021, 12, 1018.	5.8	82
128	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines, 2021, 9, 171.	2.1	43
129	SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. International Journal of Environmental Research and Public Health, 2021, 18, 1626.	1.2	17
131	Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance, 2021, 26, .	3.9	236
132	â€œCOVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatmentâ€• Archives of Dermatological Research, 2022, 314, 1-15.	1.1	99
133	mRNA Vaccines against Flaviviruses. Vaccines, 2021, 9, 148.	2.1	25
134	SARS-CoV-2 virus: Vaccines in development. Fundamental Research, 2021, 1, 131-138.	1.6	12
135	An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo. Vaccines, 2021, 9, 244.	2.1	15
137	COVID-19 Vaccine. Clinical Nurse Specialist, 2021, 35, 62-64.	0.3	0
138	COVID-19 Vaccine Race: An Overview and Update. Journal of Drug Delivery and Therapeutics, 2021, 11, 171-177.	0.2	1

#	Article	IF	Citations
139	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. International Journal of Infectious Diseases, 2021, 104, 441-451.	1.5	14
140	State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2. ACS Applied Materials & Interfaces, 2021, 13, 14816-14843.	4.0	27
141	Does COVID-19 Vaccination Warrant the Classical Principle â€œofelein i mi vlaptinâ€?. Medicina (Lithuania), 2021, 57, 253.	0.8	10
142	Adverse Events Reported From ÂCOVID-19 Vaccine Trials: A Systematic Review. Indian Journal of Clinical Biochemistry, 2021, 36, 427-439.	0.9	175
143	Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen. Frontiers in Immunology, 2021, 12, 637982.	2.2	9
144	Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control. Drug Delivery and Translational Research, 2021, 11, 1420-1437.	3.0	18
145	A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48
146	SARS-CoV-2 vaccines in patients with SLE. Lupus Science and Medicine, 2021, 8, e000479.	1.1	30
147	mRNA SARS-CoV-2 Immunization Confers Robust Antibody Response in Occupational Healthcare Workers and Fosters Workplace Safety. Journal of Occupational and Environmental Medicine, 2021, 63, e314-e317.	0.9	3
148	Caution advised when considering â€œExceptionalâ€•extended or single dose COVID-19 vaccination strategies. Travel Medicine and Infectious Disease, 2021, 40, 101994.	1.5	0
149	Advanced microscopy technologies enable rapid response to<scp>SARSâ€CoV</scp>â€2 pandemic. Cellular Microbiology, 2021, 23, e13319.	1.1	7
150	Self-assembled mRNA vaccines. Advanced Drug Delivery Reviews, 2021, 170, 83-112.	6.6	248
151	Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?. Lancet, The, 2021, 397, 879-880.	6.3	29
152	Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 2021, 33, 521-527.	1.8	19
153	Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioengineering and Translational Medicine, 2021, 6, e10213.	3.9	142
154	Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Clinical Drug Investigation, 2021, 41, 499-509.	1.1	14
155	Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. Frontiers in Immunology, 2021, 12, 657711.	2.2	50
156	Vaccines: Underlying Principles of Design and Testing. Clinical Pharmacology and Therapeutics, 2021, 109, 987-999.	2.3	2

#	Article	IF	Citations
157	A Review of the Progress of COVID-19 Vaccine Development. Duzce Universitesi Tip FakÃ¼ltesi Dergisi, 2021, 23, 1-23.	0.3	7
158	COVID-19 vaccines: rapid development, implications, challenges and future prospects. Human Cell, 2021, 34, 711-733.	1.2	227
159	Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. Microorganisms, 2021, 9, 733.	1.6	22
160	SARSâ€CoVâ€2 and pediatric solid organ transplantation: Current knowns and unknowns. Pediatric Transplantation, 2021, 25, e13986.	0.5	6
162	DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS ONE, 2021, 16, e0248007.	1.1	32
163	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	5.8	54
165	Preliminary optimisation of a simplified sample preparation method to permit direct detection of SARS-CoV-2 within saliva samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP). Journal of Virological Methods, 2021, 289, 114048.	1.0	31
166	COVID-19 in early 2021: current status and looking forward. Signal Transduction and Targeted Therapy, 2021, 6, 114.	7.1	191
168	An overview of vaccine development for COVID-19. Therapeutic Delivery, 2021, 12, 235-244.	1.2	51
169	Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics, 2021, 11, 579.	1.3	114
171	Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies. Infectious Diseases, 2021, 53, 498-512.	1.4	12
172	Does Macrophage Migration Inhibitory Factor predict the prognosis of COVID-19 disease?. Journal of Infection in Developing Countries, 2021, 15, 398-403.	0.5	8
173	An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndromeâ€“Coronavirus. Frontiers in Molecular Biosciences, 2021, 8, 637550.	1.6	8
174	Multilobed Magnetic Liposomes Enable Remotely Controlled Collection, Transport, and Delivery of Membrane-Soluble Cargos to Vesicles and Cells. ACS Applied Bio Materials, 2021, 4, 4833-4840.	2.3	3
176	The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?. Clinical Therapeutics, 2021, 43, 549-556.	1.1	13
177	Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines. Current Clinical Microbiology Reports, 2021, 8, 178-185.	1.8	46
178	Therapeutic Delivery of Pip4k2câ€Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart. Advanced Science, 2021, 8, 2004661.	5.6	14
181	Clinical and immunological effects of mRNA vaccines in malignant diseases. Molecular Cancer, 2021, 20, 52.	7.9	90

#	Article	IF	Citations
182	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2021, 593, 136-141.	13.7	648
183	Novel approaches for vaccine development. Cell, 2021, 184, 1589-1603.	13.5	145
184	Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials. Journal of College of Medical Sciences-Nepal, 2021, 11, 959-982.	0.2	17
186	Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. Current Opinion in Infectious Diseases, 2021, 34, 181-186.	1.3	34
187	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nature Communications, 2021, 12, 1403.	5.8	65
189	Nanotechnology for modern medicine: next step towards clinical translation. Journal of Internal Medicine, 2021, 290, 486-498.	2.7	88
190	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2021, 170, 113-141.	6.6	71
191	Perspectives on RNA Vaccine Candidates for COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 635245.	1.6	44
192	Precision therapeutic targets for COVID-19. Virology Journal, 2021, 18, 66.	1.4	40
193	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. Bioscience Reports, 2021, 41, .	1.1	16
195	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 2021, 7, 512-533.	5.3	217
197	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Science Advances, 2021, 7, .	4.7	100
200	The Mechanism of SARS-CoV-2 Nucleocapsid Protein Recognition by the Human 14-3-3 Proteins. Journal of Molecular Biology, 2021, 433, 166875.	2.0	61
201	The COVID-19 Vaccines: Recent Development, Challenges and Prospects. Vaccines, 2021, 9, 349.	2.1	60
204	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals, 2021, 14, 406.	1.7	101
205	A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. Virus Research, 2021, 295, 198305.	1.1	14
206	Nanocarrier vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 171, 215-239.	6.6	66
207	COVID-19 immunity and vaccines: what a pharmacist needs to know. Asian Biomedicine, 2021, 15, 51-67.	0.2	0

#	Article	IF	Citations
208	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chinese Medical Journal, 2021, 134, 1289-1298.	0.9	49
209	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. Npj Vaccines, 2021, 6, 50.	2.9	46
210	Immunology of biodegradable nanoparticles: a brief overview on a wide growing field. , 0, , 48-60.		5
212	Strategies for Immunomonitoring after Vaccination and during Infection. Vaccines, 2021, 9, 365.	2.1	12
214	Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. Journal of Pharmacy Practice, 2022, 35, 947-951.	0.5	82
215	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. PLoS Pathogens, 2021, 17, e1009064.	2.1	21
216	Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration. AAPS PharmSciTech, 2021, 22, 126.	1.5	41
217	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nature Medicine, 2021, 27, 1062-1070.	15.2	114
218	mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine, 2021, 39, 2190-2200.	1.7	214
219	A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. JCI Insight, 2021, 6, .	2.3	39
220	Exponential increase in neutralizing and spike specific antibodies following vaccination of <scp>COVID</scp>â€19 convalescent plasma donors. Transfusion, 2021, 61, 2099-2106.	0.8	27
222	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. Science Progress, 2021, 104, 003685042110169.	1.0	15
223	T lymphocytes as critical mediators in tissue regeneration, fibrosis, and the foreign body response. Acta Biomaterialia, 2021, 133, 17-33.	4.1	42
224	Positive aspects of the mRNA platform for SARS-CoV-2 vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 2445-2447.	1.4	9
225	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight, 2021, 6, .	2.3	52
226	SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. Cell Reports Medicine, 2021, 2, 100252.	3.3	33
227	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. Immunological Investigations, 2021, 50, 743-779.	1.0	16
228	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. Npj Vaccines, 2021, 6, 57.	2.9	118

#	Article	IF	Citations
229	Innate and adaptive immune responses toward nanomedicines. Acta Pharmaceutica Sinica B, 2021, 11, 852-870.	5.7	26
230	Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell, 2021, 184, 2316-2331.e15.	13.5	321
232	Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. Npj Vaccines, 2021, 6, 61.	2.9	66
233	Distinct antibody and memory B cell responses in SARS-CoV-2 naÃ¯ve and recovered individuals after mRNA vaccination. Science Immunology, 2021, 6, .	5.6	556
234	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. ACS Nano, 2021, 15, 5793-5818.	7.3	32
235	Status Report on COVID-19 Vaccines Development. Current Infectious Disease Reports, 2021, 23, 9.	1.3	56
236	mRNA therapeutics in cancer immunotherapy. Molecular Cancer, 2021, 20, 69.	7.9	168
237	A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment. Annals of Palliative Medicine, 2021, 10, 4777-4798.	0.5	9
239	To get or not to get: Examining the intentions of Philippine teachers to vaccinate against COVID-19. Journal of Human Behavior in the Social Environment, 2022, 32, 325-335.	1.1	13
240	A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. Cell, 2021, 184, 2229-2238.e13.	13.5	51
241	Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. ACS Central Science, 2021, 7, 757-767.	5.3	46
242	The importance of genomic analysis in cracking the coronavirus pandemic. Expert Review of Molecular Diagnostics, 2021, 21, 547-562.	1.5	14
243	Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nature Communications, 2021, 12, 2117.	5.8	70
245	Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. Journal of Thoracic Oncology, 2021, 16, 546-571.	0.5	25
246	Genetic Basis of Type IV Collagen Disorders of the Kidney. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1101-1109.	2.2	29
248	Influenza Virus and SARS-CoV-2 Vaccines. Journal of Immunology, 2021, 206, 2509-2520.	0.4	11
249	Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV. Briefings in Bioinformatics, 2021, 22, .	3.2	16
250	The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18â€“59Âyears: A phase I randomized, double-blinded, controlled trial. Vaccine, 2021, 39, 2746-2754.	1.7	43

#	Article	IF	Citations
251	Transcription, mRNA Export, and Immune Evasion Shape the Codon Usage of Viruses. Genome Biology and Evolution, 2021, 13, .	1.1	24
252	Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. Emerging Microbes and Infections, 2021, 10, 1002-1015.	3.0	22
253	Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet, The, 2021, 397, 1819-1829.	6.3	1,359
254	The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. International Journal of Infectious Diseases, 2021, 106, 61-64.	1.5	65
255	Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?. Blood Coagulation and Fibrinolysis, 2021, 32, 423-424.	0.5	5
256	Silencing of SARSâ€CoVâ€2 with modified siRNAâ€peptide dendrimer formulation. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2840-2854.	2.7	65
257	Chemoâ€Enzymatic Modification of the 5â€² Cap Maintains Translation and Increases Immunogenic Properties of mRNA. Angewandte Chemie - International Edition, 2021, 60, 13280-13286.	7.2	34
258	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. Archives of Pharmacal Research, 2021, 44, 499-513.	2.7	18
259	Comparative Analysis of Antigen-Specific Antiâ€“SARS-CoV-2 Antibody Isotypes in COVID-19 Patients. Journal of Immunology, 2021, 206, 2393-2401.	0.4	19
260	Seropositivity in blood donors and pregnant women during the first year of SARSâ€CoVâ€2 transmission in Stockholm, Sweden. Journal of Internal Medicine, 2021, 290, 666-676.	2.7	34
261	Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis. Vaccine, 2021, 39, 2995-3006.	1.7	71
262	Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicineâ€"Specific Cancer Targeting with Undetectable Toxicity. Chemical Reviews, 2021, 121, 7398-7467.	23.0	45
263	Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response. Journal of Infection in Developing Countries, 2021, 15, 653-656.	0.5	10
264	Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination. NeurologÃa (English Edition), 2021, 36, 451-461.	0.2	10
265	COVIDâ€19: vaccineâ€™s progress. Microbial Biotechnology, 2021, 14, 1246-1257.	2.0	16
266	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338.	6.6	75
267	The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021, 16, 630-643.	15.6	578
268	Influenza vaccines: Past, present, and future. Reviews in Medical Virology, 2022, 32, e2243.	3.9	36

#	Article	IF	Citations
269	A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses. Journal of Virology, 2021, 95, .	1.5	37
270	Eine chemoâ€enzymatische Modifizierung der 5â€²â€Kappe erhÃlt die Translation und erhÃ¶ht die ImmunogenitÃt der mRNA. Angewandte Chemie, 2021, 133, 13390-13397.	1.6	2
271	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 637-646.	4.6	326
272	Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives. World Journal of Clinical Cases, 2021, 9, 2951-2968.	0.3	8
273	Coincidental SARS-CoV-2 infection and mRNA vaccination: a case report addressing the most important clinical questions. Infection, 2021, 49, 785-788.	2.3	0
274	Resonant Acoustic Mixing Method to Produce Lipid-Based Liquid-Crystal Nanoparticles. Journal of Physical Chemistry C, 2021, 125, 10653-10664.	1.5	8
276	SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. Biomedicines, 2021, 9, 611.	1.4	10
277	Assessment of salivary antibody response to BNT162b2 mRNA COVIDâ€19 vaccination. Journal of Medical Virology, 2021, 93, 5257-5259.	2.5	18
278	Immune response scenario and vaccine development for SARS-CoV-2 infection. International Immunopharmacology, 2021, 94, 107439.	1.7	10
279	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 2021, 39, 2791-2799.	1.7	185
280	A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduction and Targeted Therapy, 2021, 6, 213.	7.1	76
281	The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 2021, 333, 511-520.	4.8	276
282	Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nature Communications, 2021, 12, 2656.	5.8	51
283	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines, 2021, 6, 74.	2.9	198
284	Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ, The, 2021, 373, n1087.	3.0	59
285	mRNA COVID-19 Vaccine for People with Kidney Failure: Hope but Prudence Warranted. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 996-998.	2.2	4
286	Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance. Frontiers in Immunology, 2021, 12, 674048.	2.2	26
287	Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2. Viruses, 2021, 13, 980.	1.5	15

#	Article	IF	Citations
289	The need for ethical and pragmatic strategies for sample and data collection during public health emergenciesâ€"minimizing missed opportunities. European Heart Journal, 2021, 42, 3114-3116.	1.0	0
290	COVID-19 vaccine decisions: considering the choices and opportunities. Microbes and Infection, 2021, 23, 104811.	1.0	17
291	Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nature Communications, 2021, 12, 3109.	5.8	118
292	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. Pharmaceuticals, 2021, 14, 520.	1.7	24
293	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. Human Genomics, 2021, 15, 27.	1.4	39
294	Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design. Acta Pharmaceutica Sinica B, 2021, 11, 3060-3091.	5.7	74
295	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines, 2021, 9, 467.	2.1	228
296	Interim Results of a Phase 1â€"2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 2021, 384, 1824-1835.	13.9	962
297	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature, 2021, 595, 572-577.	13.7	583
298	Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. Diagnostics, 2021, 11, 1190.	1.3	10
299	SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine, 2021, 68, 103410.	2.7	56
300	Review: Vaccine Myth-Buster â€" Cleaning Up With Prejudices and Dangerous Misinformation. Frontiers in Immunology, 2021, 12, 663280.	2.2	22
301	Immune memory in individuals with COVID-19. Nature Cell Biology, 2021, 23, 582-584.	4.6	5
302	Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease. Frontiers in Chemistry, 2021, 9, 692168.	1.8	75
303	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. Canadian Journal of Physiology and Pharmacology, 2021, 99, 577-588.	0.7	2
304	COVID-19 vaccination on Brazil and the crocodile side-effect. Ethics, Medicine and Public Health, 2021, 17, 100654.	0.5	7
305	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. Vaccines, 2021, 9, 588.	2.1	12
306	The Immunopathobiology of SARS-CoV-2 Infection. FEMS Microbiology Reviews, 2021, 45, .	3.9	9

#	Article	IF	Citations
307	An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. ACS Central Science, 2021, 7, 1191-1204.	5.3	34
308	Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination. Vaccines, 2021, 9, 587.	2.1	6
309	Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. Advances in Molecular Pathology, 2021, , .	0.2	1
310	COVID-19 and the Response of Transplant Centers: the Global Response with an Emphasis on the Kidney Recipient. Current Transplantation Reports, 2021, 8, 1-20.	0.9	4
311	Preparing for COVID-19 Vaccination: Guidances for Healthcare Personnel. Korean Journal of Healthcare-Associated Infection Control and Prevention, 2021, 26, 3-15.	0.1	1
312	First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers. Vaccines, 2021, 9, 659.	2.1	12
313	COVID-19 vaccines: Frequently asked questions and updated answers. Infectious Diseases Now, 2021, 51, 319-333.	0.7	10
314	Key Considerations for the Development of Safe and Effective SARSâ€CoVâ€2 Subunit Vaccine: A Peptideâ€Based Vaccine Alternative. Advanced Science, 2021, 8, e2100985.	5.6	16
315	Critical Review of the Evolution of Extracellular Vesiclesâ€™ Knowledge: From 1946 to Today. International Journal of Molecular Sciences, 2021, 22, 6417.	1.8	64
316	Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. Journal of Allergy and Clinical Immunology, 2021, 147, 2075-2082.e2.	1.5	117
317	A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. Pathogens, 2021, 10, 710.	1.2	8
318	Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring. Viruses, 2021, 13, 1232.	1.5	0
320	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). Sovremennye Tehnologii V Medicine, 2021, 13, 81.	0.4	4
321	Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies. Scientific Reports, 2021, 11, 13120.	1.6	11
322	Specific Treatment Exists for SARS-CoV-2 ARDS. Vaccines, 2021, 9, 635.	2.1	11
323	Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead. Bioengineering, 2021, 8, 84.	1.6	12
324	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. Frontiers in Immunology, 2021, 12, 710263.	2.2	32
325	Coronavirus disease 2019 vaccination in transplant recipients. Current Opinion in Infectious Diseases, 2021, 34, 275-287.	1.3	15

#	Article	IF	Citations
326	Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19. Nature Cell Biology, 2021, 23, 620-630.	4.6	67
327	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. International Journal of Pharmaceutics, 2021, 603, 120686.	2.6	83
328	A Focus on â€œBioâ€•in Bioâ€“Nanoscience: The Impact of Biological Factors on Nanomaterial Interactions. Advanced Healthcare Materials, 2021, 10, e2100574.	3.9	23
329	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature, 2021, 596, 109-113.	13.7	586
333	Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects. Vaccine, 2021, 39, 4256-4260.	1.7	20
334	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. Virology, 2021, 558, 1-12.	1.1	17
335	Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era. Open Forum Infectious Diseases, 2021, 8, ofab353.	0.4	99
336	What gastroenterologists should know about SARSâ€“CoV 2 vaccine: World Endoscopy Organization perspective. United European Gastroenterology Journal, 2021, 9, 787-796.	1.6	4
337	Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3575-3583.	2.0	41
339	Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay. Vaccines, 2021, 9, 611.	2.1	5
340	SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. Scientific Reports, 2021, 11, 11998.	1.6	17
341	Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection. Molecular Therapy - Methods and Clinical Development, 2021, 21, 754-764.	1.8	5
343	Production of Structured RNA Fragments by In Vitro Transcription and HPLC Purification. Current Protocols, 2021, 1, e159.	1.3	4
344	Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation. Nanomedicine, 2021, 16, 1219-1235.	1.7	32
345	Biomineralization: Biomimetic Synthesis of Materials and Biomimetic Regulation of Organisms. Chinese Journal of Chemistry, 2021, 39, 2071-2082.	2.6	9
346	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	64
347	Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2021, 32, 2153-2158.	3.0	140
348	Therapeutic vaccine for chronic diseases after the COVID-19 Era. Hypertension Research, 2021, 44, 1047-1053.	1.5	7

#	Article	IF	Citations
349	A rational strategy to support approved COVID-19 vaccines prioritization. Human Vaccines and Immunotherapeutics, 2021, 17, 3474-3477.	1.4	4
350	Regulation of in vivo delivery of nanomedicines by herbal medicines. Advanced Drug Delivery Reviews, 2021, 174, 210-228.	6.6	19
352	Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles. Journal of Controlled Release, 2021, 335, 465-480.	4.8	55
354	COVID-19 Vaccines: Fabrication Techniques and Current Status. Coronaviruses, 2021, 02, .	0.2	0
355	A contemporary insight into SARS-CoV-2 pathophysiology, retrieved threat of mutants and prospect of vaccine development. Minerva Biotechnology and Biomolecular Research, 2021, 33, .	0.3	7
356	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Frontiers in Immunology, 2021, 12, 701501.	2.2	157
357	Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsortâ€19 study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 271-281.	2.7	30
358	Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. Molecular Pharmaceutics, 2021, 18, 2867-2888.	2.3	65
359	Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers. Nature Communications, 2021, 12, 4396.	5.8	24
360	SARS-CoV-2 serology testing: Progress and challenges. Journal of Immunological Methods, 2021, 494, 113060.	0.6	21
361	Profiling SARS-CoV-2 HLA-I peptidome reveals TÂcell epitopes from out-of-frame ORFs. Cell, 2021, 184, 3962-3980.e17.	13.5	98
362	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathogens, 2021, 17, e1009761.	2.1	66
363	Development and Delivery Systems of mRNA Vaccines. Frontiers in Bioengineering and Biotechnology, 2021, 9, 718753.	2.0	60
364	Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infectious Diseases of Poverty, 2021, 10, 94.	1.5	109
365	Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?. Vaccines, 2021, 9, 761.	2.1	17
366	Lessons Learned from Postâ€"COVID-19 Vaccination PET/CT Studies. Journal of Nuclear Medicine, 2022, 63, 453-460.	2.8	21
367	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert Review of Anti-Infective Therapy, 2021, 19, 1219-1244.	2.0	6
368	Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?. Infection, 2022, 50, 11-25.	2.3	50

#	Article	IF	Citations
370	Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies. Frontiers in Immunology, 2021, 12, 705360.	2.2	48
371	Principles and Methods of Counteracting Harmful Salmonâ€“Arthropod Interactions in Salmon Farming: Addressing Possibilities, Limitations, and Future Options. Frontiers in Marine Science, 2021, 8, .	1.2	7
372	Predictive Analytics of COVID-19 with Neural Networks. , 2021, , .		7
373	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nature Medicine, 2021, 27, 1744-1751.	15.2	148
374	Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature, 2021, 596, 410-416.	13.7	313
375	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 950-961.	4.6	271
376	Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia, 2021, 35, 3534-3541.	3.3	71
377	Antibody Response against the SARS-CoV-2 Nucleocapsid Protein and Its Subdomainsâ€”Identification of Pre-Immunization Status by Human Coronaviruses with Multipanel Nucleocapsid Fragment Immunoblotting. Covid, 2021, 1, 105-114.	0.7	6
378	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. Molecular Biology, 2021, 55, 538-547.	0.4	2
379	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 121-130.	6.3	316
380	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. ACS Infectious Diseases, 2021, 7, 2546-2564.	1.8	34
381	Shedding UVC light on Covid-19 to protect dentistry staff and patients. Laser Physics Letters, 2021, 18, 085602.	0.6	2
382	Accelerating vaccine trial conduct in a pandemic with a hot spotâ€based inclusion strategy using trial and epidemic simulation. Clinical and Translational Science, 2021, 14, 2391-2398.	1.5	6
383	Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. Expert Review of Precision Medicine and Drug Development, 2021, 6, 281-294.	0.4	4
384	Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance. IScience, 2021, 24, 102780.	1.9	4
385	COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nature Medicine, 2021, 27, 1385-1394.	15.2	704
387	Safety and effectiveness of SARSâ€CoVâ€2 vaccines: A systematic review and metaâ€analysis. Journal of Medical Virology, 2021, 93, 6486-6495.	2.5	58
388	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Research, 2021, 31, 1011-1023.	5.7	48

#	Article	IF	Citations
390	The role of micronutrient and immunomodulation effect in the vaccine era of COVID-19. Journal of the Chinese Medical Association, 2021, 84, 821-826.	0.6	19
393	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology, 2021, 21, 475-484.	10.6	434
394	Detection of SARS-CoV-2-Specific IgA in the Human Milk of COVID-19 Vaccinated Lactating Health Care Workers. Breastfeeding Medicine, 2021, 16, 1004-1009.	0.8	34
395	Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials. Vaccines, 2021, 9, 939.	2.1	25
396	FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med, 2021, 2, 979-992.e8.	2.2	127
397	Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics. Pharmaceutics, 2021, 13, 1365.	2.0	61
398	In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry. Turkish Journal of Biology, 2021, 45, 442-458.	2.1	3
399	Immunity to SARSâ€CoVâ€2 induced by infection or vaccination. Journal of Internal Medicine, 2022, 291, 32-50.	2.7	97
400	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infectious Diseases, The, 2021, 21, 1107-1119.	4.6	345
401	Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med, 2021, 2, 965-978.e5.	2.2	40
402	Significant Publications on Infectious Diseases Pharmacotherapy in 2020. Journal of Pharmacy Practice, 2023, 36, 394-406.	0.5	1
403	Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. Nature Nanotechnology, 2021, 16, 843-850.	15.6	40
406	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight, 2021, 6, .	2.3	33
407	Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series. Transplantation Direct, 2021, 7, e743.	0.8	3
408	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. Infection, Genetics and Evolution, 2021, 92, 104869.	1.0	49
410	An Update on mRNA-Based Viral Vaccines. Vaccines, 2021, 9, 965.	2.1	14
412	Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19. Vaccines, 2021, 9, 947.	2.1	19
413	Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. Journal of Autoimmunity, 2021, 122, 102685.	3.0	53

#	Article	IF	Citations
414	Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan. Journal of Infection and Chemotherapy, 2021, 27, 1713-1715.	0.8	8
415	Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses, 2021, 13, 1645.	1.5	8
416	Antibody and TÂcell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell, 2021, 39, 1034-1036.	7.7	132
417	Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles. International Journal of Nanomedicine, 2021, Volume 16, 5981-6002.	3.3	37
418	Qualitative Assessment of Early Adverse Effects of Pfizerâ€"BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews. Vaccines, 2021, 9, 950.	2.1	18
419	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Reports, 2021, 36, 109493.	2.9	46
420	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 2021, 20, 817-838.	21.5	577
421	Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. Journal of the American Society of Nephrology: JASN, 2021, 32, 2735-2742.	3.0	64
422	Connecting primitive phase separation to biotechnology, synthetic biology, and engineering. Journal of Biosciences, 2021, 46, 1.	0.5	11
423	Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge. Vaccines, 2021, 9, 881.	2.1	86
424	Acidic pH-induced changes in lipid nanoparticle membrane packing. Biochimica Et Biophysica Acta - Biomembranes, 2021, 1863, 183627.	1.4	11
426	Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. International Immunopharmacology, 2021, 97, 107622.	1.7	14
427	Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies. PLoS ONE, 2021, 16, e0255622.	1.1	21
429	Response to â€œSafety and effectiveness of SARSâ€CoVâ€2 vaccines: A systematic review and metaâ€analysisâ€. Journal of Medical Virology, 2021, 93, 6477-6478.	2.5	0
430	Strategies to load therapeutics into polysaccharide-based nanogels with a focus on microfluidics: A review. Carbohydrate Polymers, 2021, 266, 118119.	5.1	11
431	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines, 2021, 9, 848.	2.1	64
432	Review Article: vaccination for patients with inflammatory bowel disease during the COVIDâ€19 pandemic. Alimentary Pharmacology and Therapeutics, 2021, 54, 1110-1123.	1.9	26
434	Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	23

#	Article	IF	Citations
435	Antibody response and self-reported adverse reactions following vaccination with Comirnaty: a pilot study from a Croatian university hospital. Journal of Clinical Pathology, 2022, 75, 782-786.	1.0	10
436	A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice. Virologica Sinica, 2021, 36, 1113-1123.	1.2	11
437	COVID-19 Vaccines: Current Conditions and Future Prospects. Biology, 2021, 10, 960.	1.3	14
438	Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer. European Journal of Cancer, 2021, 154, 66-72.	1.3	31
439	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Science Immunology, 2021, 6, eabl4509.	5.6	141
440	Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Frontiers in Immunology, 2021, 12, 742914.	2.2	52
441	IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. Vaccines, 2021, 9, 999.	2.1	23
443	Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Regional Health - Europe, The, 2021, 10, 100208.	3.0	446
444	How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream. Pharmaceutical Medicine, 2021, 35, 287-295.	1.0	1
446	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Science Advances, 2021, 7, eabg7996.	4.7	20
447	Single Micelle Vectors based on Lipid/Block Copolymer Compositions as mRNA Formulations for Efficient Cancer Immunogene Therapy. Molecular Pharmaceutics, 2021, 18, 4029-4045.	2.3	13
448	RNA Therapeutics - Research and Clinical Advancements. Frontiers in Molecular Biosciences, 2021, 8, 710738.	1.6	39
449	BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respiratory Medicine,the, 2021, 9, 999-1009.	5.2	279
450	Trends in psychological distress and COVID-19 incidence across 15 U.S. metropolitan statistical areas in 2020. Social Science and Medicine, 2021, 285, 114285.	1.8	7
452	Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2. International Journal of Infectious Diseases, 2021, 113, 233-235.	1.5	27
453	Optimising SARS-CoV-2 vaccination schedules. Lancet, The, 2021, 398, 819-821.	6.3	3
454	Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. Medicina (Lithuania), 2021, 57, 997.	0.8	9
455	Evaluation of adverse effects withÂCOVID-19 vaccination in Pakistan. Pakistan Journal of Medical Sciences, 2021, 37, 1959-1964.	0.3	15

#	Article	IF	Citations
456	Clinical trial research on COVID-19 in Germany â€“ a systematic analysis. F1000Research, 0, 10, 913.	0.8	5
457	Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. Molecules and Cells, 2021, , .	1.0	3
458	Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches. MSystems, 2021, 6, e0038821.	1.7	10
459	Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. Advanced Drug Delivery Reviews, 2021, 176, 113889.	6.6	48
460	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	15.2	900
461	Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study. Vaccine, 2021, 39, 6535-6538.	1.7	30
462	Possibility of new shielding device for upper gastrointestinal endoscopy. Endoscopy International Open, 2021, 09, E1536-E1541.	0.9	7
463	Secret messengers: Extracellular RNA communication in the immune system*. Immunological Reviews, 2021, 304, 62-76.	2.8	12
464	Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. JCI Insight, 2021, 6, .	2.3	18
465	Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients. Kidney International, 2021, 100, 698-700.	2.6	8
466	Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2021, 148, 1192-1197.	1.5	67
467	COVID-19 Vaccines: Speedy Development and their Use to be Saviour of Humanity. The National Academy of Sciences, India, 2021, , 1-5.	0.8	2
468	Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection. Vaccines, 2021, 9, 1028.	2.1	11
469	National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. Public Health, 2021, 198, 102-105.	1.4	4
470	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. International Immunology, 2021, 33, 529-540.	1.8	28
471	Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1â€“2, dose-ranging study. Lancet Infectious Diseases, The, 2021, 21, 1257-1270.	4.6	99
472	Nucleic acid delivery for therapeutic applications. Advanced Drug Delivery Reviews, 2021, 178, 113834.	6.6	122
473	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. Frontiers in Immunology, 2021, 12, 708848.	2.2	7

#	Article	IF	Citations
474	Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports. Vaccines, 2021, 9, 1013.	2.1	83
475	Lipid Self-Assemblies under the Atomic Force Microscope. International Journal of Molecular Sciences, 2021, 22, 10085.	1.8	5
476	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiology Spectrum, 2021, 9, e0034121.	1.2	114
477	Synthetic modified messenger RNA for therapeutic applications. Acta Biomaterialia, 2021, 131, 1-15.	4.1	34
478	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Frontiers in Cellular and Infection Microbiology, 2021, 11, 690621.	1.8	60
479	SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms. Nature Communications, 2021, 12, 5621.	5.8	63
480	Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. Molecules and Cells, 2021, 44, 688-695.	1.0	11
481	An immunologist's perspective on anti-COVID-19 vaccines. Current Opinion in Allergy and Clinical Immunology, 2021, Publish Ahead of Print, 545-552.	1.1	4
482	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. International Journal of Biological Macromolecules, 2021, 188, 740-750.	3.6	83
483	Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomedicine and Pharmacotherapy, 2021, 142, 111953.	2.5	64
484	Equitable Implementation of Artificial Intelligence in Medical Imaging: What Can be Learned from Implementation Science?. PET Clinics, 2021, 16, 643-653.	1.5	5
485	Herpes zoster after COVID vaccination. International Journal of Infectious Diseases, 2021, 111, 169-171.	1.5	48
486	Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination. Annals of Allergy, Asthma and Immunology, 2021, 127, 501-503.	0.5	19
487	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
488	Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, 132, e139-e142.	0.2	35
489	Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults. Vaccine, 2021, 39, 6210-6212.	1.7	6
490	Programmable technologies to manipulate gene expression at the RNA level. Current Opinion in Chemical Biology, 2021, 64, 27-37.	2.8	2
491	Underrepresentation of older adults in clinical trials on COVID-19 vaccines: A systematic review. Ageing Research Reviews, 2021, 71, 101455.	5.0	26

#	Article	IF	Citations
492	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. International Immunopharmacology, 2021, 100, 108162.	1.7	65
493	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. Virology, 2021, 563, 134-145.	1.1	74
494	Mathematical modelling of SARS-CoV-2 infection of human and animal host cells reveals differences in the infection rates and delays in viral particle production by infected cells. Journal of Theoretical Biology, 2021, 531, 110895.	0.8	5
496	The COVID-19 vaccine: A race nearing the finish line. Apollo Medicine, 2021, .	0.0	1
497	Lethal Human Coronavirus Infections and the Role of Vaccines in Their Prevention. , 2021, , 533-549.		1
498	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. Oxford Open Immunology, 2021, 2, iqab010.	1.2	18
499	mRNA-Enhanced Cell Therapy and Cardiovascular Regeneration. Cells, 2021, 10, 187.	1.8	16
500	Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100026.	1.7	21
501	Current State of the First COVID-19 Vaccines. Vaccines, 2021, 9, 30.	2.1	64
504	Could Vaccine Dose Stretching Reduce COVID-19 Deaths?. SSRN Electronic Journal, 0, , .	0.4	1
506	Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate. Vaccines, 2021, 9, 76.	2.1	28
509	Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic. Immune Network, 2021, 21, e5.	1.6	21
510	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Molecular Biomedicine, 2021, 2, 1.	1.7	20
511	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. Pathogens, 2021, 10, 138.	1.2	60
512	Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors. Viruses, 2021, 13, 173.	1.5	37
513	Advances in vaccination to combat pandemic outbreaks. , 2021, , 123-137.		1
515	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. Science China Life Sciences, 2020, 63, 1833-1849.	2.3	29
516	All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature, 2020, 586, 501-502.	13.7	23

#	Article	IF	Citations
549	Mucin signature as a potential tool to predict susceptibility to COVIDâ€19. Physiological Reports, 2021, 9, e14701.	0.7	24
551	Nature Of, Immune Reaction and Side Effects of COVID-19 Vaccines: Synthesis of Information from Ten Phase II Trials for Planning Vaccination Programmes. SSRN Electronic Journal, 0, , .	0.4	3
552	Nano COVID-19 Vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history - Review. Research, Society and Development, 2020, 9, e20191211123.	0.0	7
553	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. International Journal of Molecular Sciences, 2020, 21, 9775.	1.8	40
554	SARS-CoV-2 Spike Protein and Lung Vascular Cells. Journal of Respiration, 2021, 1, 40-48.	0.4	6
555	Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. Vaccines, 2020, 8, 783.	2.1	13
556	Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. Vaccines, 2021, 9, 3.	2.1	74
557	Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian Journal of Medical Research, 2021, 153, 93.	0.4	28
558	Efficacy and safety of COVID-19 vaccines: a systematic review. Chinese Journal of Contemporary Pediatrics, 2021, 23, 221-228.	0.2	81
559	An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100063.	1.7	7
561	Effectiveness of COVIDâ€'19 vaccines and their challenges (Review). Experimental and Therapeutic Medicine, 2021, 22, 1407.	0.8	23
562	Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers. Journal of the American Chemical Society, 2021, 143, 17975-17982.	6.6	48
563	BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease. Vaccines, 2021, 9, 1164.	2.1	8
564	Quantitative serological evaluation as a valuableÂtool in the COVID-19 vaccination campaign. Clinical Chemistry and Laboratory Medicine, 2021, 59, 2019-2026.	1.4	11
565	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. Nano Research, 2022, 15, 2196-2225.	5.8	8
566	Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review. Value in Health, 2021, , .	0.1	7
567	Innovations and development of Covid-19 vaccines: A patent review. Journal of Infection and Public Health, 2022, 15, 123-131.	1.9	27
568	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell, 2021, 39, 1442-1444.	7.7	62

#	Article	IF	Citations
570	SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA. PLoS Biology, 2021, 19, e3001425.	2.6	71
572	Qualitative assessment of antiâ€šSARSâ€CoVâ€2 spike protein immunogenicity (QUASI) after COVIDâ€19 vaccination in older people living with HIV. HIV Medicine, 2022, 23, 178-185.	1.0	25
573	A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. Pharmaceutics, 2021, 13, 1759.	2.0	42
574	In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?. World Journal of Hepatology, 2021, 13, 1234-1268.	0.8	6
575	Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discovery, 2021, 7, 99.	3.1	58
576	Adequate immune response after SARSâ€CoVâ€2 infection and single dose vaccination despite rapid heart transplantation. ESC Heart Failure, 2021, 8, 5568.	1.4	2
577	Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. Journal of Clinical Investigation, 2021, 131, .	3.9	17
578	Single BNT162b2 vaccine dose produces seroconversion in under 60Âs cohort. Vaccine, 2021, 39, 6902-6906.	1.7	6
579	Geospatial Distribution of Ophthalmologists Older than Age 60 Years Relative to the Prevalence of COVID-19. Ophthalmic Surgery Lasers and Imaging Retina, 2021, 52, 556-559.	0.4	0
580	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines ComirnatyÂ® and COVID-19 mRNA Vaccine ModernaÂ®. Trials, 2021, 22, 724.	0.7	9
581	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 714170.	2.2	145
582	Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. Journal of Community Health, 2022, 47, 211-225.	1.9	30
583	Vaccines against COVID-19: Priority to mRNA-Based Formulations. Cells, 2021, 10, 2716.	1.8	17
585	Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respiratory Medicine,the, 2021, 9, 1396-1406.	5.2	105
586	Myopericarditis with Significant Left Ventricular Dysfunction Following COVID-19 Vaccination: A Case Report. American Journal of Case Reports, 2021, 22, e934066.	0.3	3
587	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement. Vaccines, 2021, 9, 1211.	2.1	5
588	Kidney transplant recipientsâ€™ attitudes towards covidâ€19 vaccination and barriers and enablers to vaccine acceptance. Transplant Infectious Disease, 2021, , e13749.	0.7	12
590	Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants. Frontiers in Cellular and Infection Microbiology, 2021, 11, 745016.	1.8	36

#	Article	IF	Citations
591	COVID-19 mRNA vaccine allergy. Current Opinion in Pediatrics, 2021, 33, 610-617.	1.0	15
592	Recent Update of COVID-19 Vaccines. Advanced Pharmaceutical Bulletin, 2021, , .	0.6	0
594	Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2. Journal of Medicinal Chemistry, 2021, 64, 14955-14967.	2.9	28
595	Development of synthetic antigen vaccines for COVID-19. Human Vaccines and Immunotherapeutics, 2021, 17, 3855-3870.	1.4	4
596	Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2. Annals of Neurosciences, 2021, 28, 201-218.	0.9	7
597	mRNA â€“ A game changer in regenerative medicine, cell-based therapy and reprogramming strategies. Advanced Drug Delivery Reviews, 2021, 179, 114002.	6.6	25
598	Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. Journal of Autoimmunity, 2021, 125, 102742.	3.0	42
599	Combining an optimized mRNA template with a double purification process allows strong expression of inÂvitro transcribed mRNA. Molecular Therapy - Nucleic Acids, 2021, 26, 945-956.	2.3	21
600	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. Biomedicine and Pharmacotherapy, 2021, 144, 112282.	2.5	10
601	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. International Immunopharmacology, 2021, 101, 108232.	1.7	14
603	Vaccine development and technology for SARSâ€CoVâ€2: Current insight. Journal of Medical Virology, 2022, 94, 878-896.	2.5	8
604	SARS-CoV-2 infection despite high levels of vaccine-induced anti-Receptor-Binding-Domain antibodies: a study on 1110 health-care professionals from a northern Italian university hospital. Clinical Microbiology and Infection, 2022, 28, 305-307.	2.8	5
605	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. Npj Vaccines, 2021, 6, 128.	2.9	102
606	Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine; a case report. Human Vaccines and Immunotherapeutics, 2021, 17, 4099-4101.	1.4	10
607	COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre. International Journal of Cardiology Congenital Heart Disease, 2021, 6, 100266.	0.2	6
608	Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses. PPAR Research, 2021, 2021, 1-28.	1.1	8
609	Seroconversion rate after vaccination against COVID-19 in patients with cancerâ€”a systematic review. Annals of Oncology, 2022, 33, 158-168.	0.6	59
611	Effect of Sample Concentration on Nanoparticle Tracking Analysis of Small Extracellular Vesicles and Liposomes Mimicking the Physicochemical Properties of Exosomes. Chemical and Pharmaceutical Bulletin, 2021, 69, 1045-1053.	0.6	5

#	Article	IF	Citations
612	Anesthesiologistâ€™s Prospective on Self-protection, Therapy, and Managements in Global Counterattack on Coronavirus Disease-19. Journal of Clinical Research in Anesthesiology, 2020, 3, .	0.1	1
614	Vaccines and Treatment of Coronavirus Disease 2019. Korean Journal of Medicine, 2020, 95, 364-369.	0.1	1
616	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medicinski Podmladak, 2021, 72, 20-29.	0.2	3
617	The race to find COVID-19 Vaccine: So near, yet so far!. Indian Journal of Medical Specialities, 2020, 11, 175.	0.1	1
618	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). Juvenis Scientia, 2020, 6, 41-80.	0.1	0
619	A Digital Health System for Disease Analytics. , 2021, , .		10
620	Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients. Journal of Drug Delivery Science and Technology, 2022, 67, 102967.	1.4	19
621	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity, 2021, 54, 2877-2892.e7.	6.6	260
622	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. Scientific Reports, 2021, 11, 21849.	1.6	26
623	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age. Vaccines, 2021, 9, 1277.	2.1	1
628	Outbreak of infections with the COVID-19 virus mutation B.1.351 about four weeks after the second successful vaccination with BNT162b2. GMS Hygiene and Infection Control, 2021, 16, Doc16.	0.2	0
629	Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, Ribonuclease I and Human RNase A. Frontiers in Microbiology, 2021, 12, 660149.	1.5	1
630	Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. Journal of Controlled Release, 2022, 341, 206-214.	4.8	27
631	RNA-based vaccines against SARS-CoV-2. , 2022, , 129-152.		1
632	T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transplant Immunology, 2022, 70, 101495.	0.6	58
633	Analyzing Sentiments and Diffusion Characteristics of COVID-19 Vaccine Misinformation Topics in Social Media. International Journal of Business Analytics, 2021, 9, 1-22.	0.2	10
635	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines, 2021, 9, 1345.	2.1	22
636	Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine. Vaccines, 2021, 9, 1357.	2.1	24

#	Article	IF	Citations
637	Multifunctional Dendronized Polypeptides for Controlled Adjuvanticity. Biomacromolecules, 2021, , .	2.6	5
638	Comments on Thrombosis After Vaccination: The Leader Sequence of the Spike Protein Might Be Responsible for Thrombosis and Antibody-Mediated Thrombocytopenia. Viral Immunology, 2021, , .	0.6	1
639	A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 2023, 41, 550-559.	2.0	5
640	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines, 2021, 9, 1387.	2.1	51
641	Developmental Aspects of SARS-CoV-2, Potential Role of Exosomes and Their Impact on the Human Transcriptome. Journal of Developmental Biology, 2021, 9, 54.	0.9	5
642	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. Biomedicines, 2021, 9, 1740.	1.4	16
643	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	2.7	72
644	Nucleoside-Modified mRNA Vaccines Protect IFNAR ^{â€"/â€"} Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. Journal of Virology, 2022, 96, JVI0156821.	1.5	24
645	COVID-19 pandemic sentiment and stock market behavior: evidence from an emerging market. Review of Behavioral Finance, 2023, 15, 176-204.	1.2	3
646	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. Pathogens, 2021, 10, 1537.	1.2	19
647	Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12â€"18 Years in Saudi Arabia. Vaccines, 2021, 9, 1297.	2.1	33
648	Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics. Advanced Drug Delivery Reviews, 2022, 181, 114041.	6.6	26
649	Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population. Vaccines, 2021, 9, 1375.	2.1	37
650	High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Microbiology Spectrum, 2021, 9, e0096521.	1.2	17
652	Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2. Biotechnology Letters, 2021, , 1.	1.1	13
653	Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study. SSRN Electronic Journal, 0, , .	0.4	1
654	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale, 2022, 14, 1054-1074.	2.8	22
655	Microemulsion Based Nanostructures for Drug Delivery. Frontiers in Nanotechnology, 2022, 3, .	2.4	4

#	Article	IF	Citations
656	A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis. Frontiers in Immunology, 2021, 12, 769011.	2.2	21
657	Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2022, 58, 103486.	0.9	19
659	Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. Journal of Controlled Release, 2022, 342, 345-361.	4.8	82
660	Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages. Molecular Therapy - Nucleic Acids, 2022, 27, 854-869.	2.3	21
662	Predictive Analytics to Support Health Informatics on COVID-19 Data. , 2021, , .		6
663	Combating Infectious Diseases with Synthetic Biology. ACS Synthetic Biology, 2022, , .	1.9	1
664	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS) Tj ETQq0 0 0 rgBT /Overlock 1 Lancet Infectious Diseases, The, 2022, 22, 636-648.	4.6	52
665	The Evolution and Disparities of Online Attitudes Toward COVID-19 Vaccines: Year-long Longitudinal and Cross-sectional Study. Journal of Medical Internet Research, 2022, 24, e32394.	2.1	10
666	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe, The, 2022, 3, e193-e202.	3.4	45
669	Response to and outcomes of the Pfizer <scp>BNT162B2</scp> vaccine in hemodialysis patientsâ€"A prospective observational study. Hemodialysis International, 2022, 26, 216-222.	0.4	6
670	Engineering optimal vaccination strategies: effects of physical properties of the delivery system on functions. Biomaterials Science, 2022, 10, 1408-1422.	2.6	6
671	Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Microbiology Spectrum, 2022, 10, e0118121.	1.2	15
672	Induction of humoral and cellular immune responses to COVIDâ€19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers. Journal of Medical Virology, 2022, 94, 2008-2018.	2.5	11
674	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
675	TNFÎ±-Producing CD4 ⁺ T Cells Dominate the SARS-CoV-2-Specific T Cell Response in COVID-19 Outpatients and Are Associated with Durable Antibodies. SSRN Electronic Journal, 0, , .	0.4	0
676	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nano-Micro Letters, 2022, 14, 41.	14.4	26
677	<scp>COVID</scp>â€19 vaccines and risks of hematological abnormalities: Nested caseâ€"control and selfâ€controlled case series study. American Journal of Hematology, 2022, 97, 470-480.	2.0	37
678	Covid-19 vaccines production and societal immunization under the serendipity-mindsponge-3D knowledge management theory and conceptual framework. Humanities and Social Sciences Communications, 2022, 9, .	1.3	85

#	Article	IF	Citations
679	Socio-Demographic Characteristics of COVID-19 Vaccine Recipients in Kwara State, North Central Nigeria. Frontiers in Public Health, 2021, 9, 773998.	1.3	2
680	A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology Assays. Microbiology Spectrum, 2022, 10, e0156421.	1.2	8
681	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell Reports, 2022, 38, 110235.	2.9	35
682	Impact of Coronavirus Infectious Disease (COVID-19) pandemic on willingness of immunizationâ€"A community-based questionnaire study. PLoS ONE, 2022, 17, e0262660.	1.1	5
683	Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. Frontiers in Immunology, 2021, 12, 766278.	2.2	13
686	RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. BMC Infectious Diseases, 2022, 22, 87.	1.3	26
687	Hidden Beauty, Assembling Lipids: Modular Hands-On Outreach Experiments Showcasing Lipid Assembly Chemistry. Journal of Chemical Education, 2022, 99, 1087-1094.	1.1	0
688	Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2022, 20, 1534-1541.e4.	2.4	23
689	mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annual Review of Medicine, 2022, 73, 17-39.	5.0	120
690	Spike Protein IgG Antibody Immune Response Following SARS-CoV-2 Vaccination and Individual Factors Related to Its Level. Health Evaluation and Promotion, 2022, , .	0.0	1
691	The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients. Cureus, 2022, 14, e21485.	0.2	10
692	Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants. Frontiers in Immunology, 2021, 12, 803647.	2.2	7
693	COVID-19 Vaccination-Induced Myopericarditis: An Imagerâ€™s Perspective. CJC Open, 2022, 4, 497-500.	0.7	7
694	A Case of Giant Cell Arteritis Presenting After COVID-19 Vaccination: Is it Just a Coincidence?. Cureus, 2022, 14, e21608.	0.2	6
695	Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses, 2022, 14, 144.	1.5	12
696	Narrative Review: Addressing Covid-19 Vaccine Concerns in Special and Vulnerable Populations. Hospital Pharmacy, 0, , 001857872110664.	0.4	0
697	Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS ONE, 2022, 17, e0260733.	1.1	60
698	Insight into COVID-19's epidemiology, pathology, and treatment. Heliyon, 2022, 8, e08799.	1.4	19

#	Article	IF	Citations
699	Cytolysin A (ClyA): A Bacterial Virulence Factor with Potential Applications in Nanopore Technology, Vaccine Development, and Tumor Therapy. Toxins, 2022, 14, 78.	1.5	7
700	Fully Automated Chemiluminescence Microarray Analysis Platform for Rapid and Multiplexed SARS-CoV-2 Serodiagnostics. Analytical Chemistry, 2022, 94, 2855-2864.	3.2	4
701	Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice. Vaccine, 2022, 40, 854-861.	1.7	5
702	17th Annual Meeting of the Oligonucleotide Therapeutics Society: A Tribute to Bob Letsinger, Progress in Nâ€‰=â€‰1 Treatments, and Successful First In-Humans CRISPR Trials. Nucleic Acid Therapeutics, 2022, 32, 1-7.	2.0	0
703	Peopleâ€™s perceptions of, willingness-to-take preventive remedies and their willingness-to-vaccinate during times of heightened health threats. PLoS ONE, 2022, 17, e0263351.	1.1	7
704	SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study. Journal of Infectious Diseases, 2022, , .	1.9	6
705	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. VirusDisease, 2022, 33, 1-22.	1.0	47
706	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. Med, 2022, 3, 188-203.e4.	2.2	11
707	Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infectionâ€”A comparative study from Novi Sad, Serbia. PLoS ONE, 2022, 17, e0263468.	1.1	33
708	Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains. Nano Today, 2022, 43, 101393.	6.2	2
709	COVID-19 vaccine therapeutic trials review: published results and registered protocols. Journal of Global Health Reports, 0, 5, .	1.0	0
710	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). Clinical Infectious Diseases, 2022, 75, e630-e644.	2.9	65
711	The impact of <scp>COVID</scp>â€19 vaccine on sperm quality. International Journal of Gynecology and Obstetrics, 2022, 158, 116-120.	1.0	25
712	Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe, The, 2022, 3, e173-e183.	3.4	31
713	Association of COVID-19 vaccination with herpes zoster: a systematic review and meta-analysis. Expert Review of Vaccines, 2022, 21, 601-608.	2.0	11
714	Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2. PLoS ONE, 2022, 17, e0262922.	1.1	10
718	Nanotechnology Toolkit for Combating COVIDâ€19 and Beyond. ChemNanoMat, 2022, 8, e202100505.	1.5	7
719	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2â€“experienced individuals. Science Translational Medicine, 2022, 14, .	5.8	65

#	Article	IF	Citations
720	CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2022, , 1-10.	1.4	0
721	Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial. Infectious Diseases of Poverty, 2021, 10, 138.	1.5	16
723	Vaccine efficacy in mutant SARS-CoV-2 variants. , 2021, 4, 1-12.		4
724	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. Science Translational Medicine, 2021, , eabi8961.	5.8	22
725	Optimal strategy for a dose-escalation vaccination against COVID-19 in refugee camps. AIMS Mathematics, 2022, 7, 9288-9310.	0.7	5
726	Intubation and mortality prediction in hospitalized COVID-19 patients using a combination of convolutional neural network-based scoring of chest radiographs and clinical data. BJR|Open, 2022, 4, .	0.4	6
727	Stabilization of the SARS-CoV-2 receptor binding domain by protein core redesign and deep mutational scanning. Protein Engineering, Design and Selection, 2022, 35, .	1.0	8
729	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
730	Probabilistic classification of antiâ€SARSâ€CoVâ€2 antibody responses improves seroprevalence estimates. Clinical and Translational Immunology, 2022, 11, e1379.	1.7	4
731	SARS-CoV-2 infection rates after different vaccination schemes: An online survey in Turkey. Asian Pacific Journal of Tropical Medicine, 2022, 15, 171.	0.4	0
732	A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines. Journal of Primary Care and Community Health, 2022, 13, 215013192210892.	1.0	21
733	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110566.	0.7	13
734	Curvature effects in charge-regulated lipid bilayers. Soft Matter, 2022, 18, 2597-2610.	1.2	8
735	Incidence of adverse reactions to COVID-19 vaccination: A meta-analysis of randomized controlled trials. Journal of Acute Disease, 2022, 11, 1.	0.0	0
736	Next generation self-replicating RNA vectors for vaccines and immunotherapies. Cancer Gene Therapy, 2023, 30, 785-793.	2.2	9
737	Cutaneous reactions to COVID-19 vaccines: A review. JAAD International, 2022, 7, 178-186.	1.1	24
738	In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity. Viruses, 2022, 14, 389.	1.5	2
739	Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccineâ€"A Study Protocol. Frontiers in Medicine, 2022, 9, 761655.	1.2	4

#	Article	IF	Citations
740	mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases. Viruses, 2022, 14, 401.	1.5	30
742	Novel Strategies of Immunization against COVID-19. Journal of Pure and Applied Microbiology, 2022, 16, 35-49.	0.3	0
743	Fast microwave heating-based one-step synthesis of DNA and RNA modified gold nanoparticles. Nature Communications, 2022, 13, 968.	5.8	31
744	Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease. Vaccines, 2022, 10, 298.	2.1	1
745	SARS-CoV-2 Immunization Orchestrates the Amplification of IFNÎ³-Producing T Cell and NK Cell Persistence. Frontiers in Immunology, 2022, 13, 798813.	2.2	9
747	Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. International Journal of Environmental Research and Public Health, 2022, 19, 2392.	1.2	11
748	Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Current Issues in Molecular Biology, 2022, 44, 1115-1126.	1.0	63
749	Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. Cellular and Molecular Life Sciences, 2022, 79, 142.	2.4	24
750	Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study. BMC Infectious Diseases, 2022, 22, 179.	1.3	18
751	Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System. Vaccines, 2022, 10, 345.	2.1	13
752	A Case With New-Onset Neuromyelitis Optica Spectrum Disorder Following COVID-19 mRNA BNT162b2 Vaccination. Neurologist, 2022, 27, 147-150.	0.4	20
753	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. Vaccines, 2022, 10, 313.	2.1	5
755	Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review. Human Vaccines and Immunotherapeutics, 2022, 18, 1-8.	1.4	1
756	Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines. Archives of Pathology and Laboratory Medicine, 2022, 146, 677-685.	1.2	7
757	Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls. Frontiers in Immunology, 2022, 13, 832501.	2.2	23
758	Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection, 2022, 50, 1399-1404.	2.3	20
759	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clinical Infectious Diseases, 2022, 75, e585-e593.	2.9	26
760	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. Human Vaccines and Immunotherapeutics, 2022, 18, 2040330.	1.4	5

#	Article	IF	Citations
761	Immunogenic Epitope-Based Vaccine Prediction from Surface Glycoprotein of MERS-CoV by Deploying Immunoinformatics Approach. International Journal of Peptide Research and Therapeutics, 2022, 28, 77.	0.9	5
762	Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein. Vaccines, 2022, 10, 504.	2.1	8
763	IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nature Immunology, 2022, 23, 532-542.	7.0	178
764	Current Status and Future Perspectives on MRNA Drug Manufacturing. Molecular Pharmaceutics, 2022, 19, 1047-1058.	2.3	44
765	mRNA Lipoplexes with Cationic and Ionizable Î±-Amino-lipophosphonates: Membrane Fusion, Transfection, mRNA Translation and Conformation. Pharmaceutics, 2022, 14, 581.	2.0	3
766	A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerging Microbes and Infections, 2022, 11, 1058-1071.	3.0	63
767	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. Journal of Microbiology, 2022, 60, 308-320.	1.3	6
768	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. International Journal of Molecular Sciences, 2022, 23, 3338.	1.8	11
769	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. PeerJ, 2022, 10, e13083.	0.9	14
771	Current Developments and Challenges of mRNA Vaccines. Annual Review of Biomedical Engineering, 2022, 24, 85-109.	5.7	39
773	Detection, prevention and treatment of COVIDâ€19 and opportunities for nanobiotechnology. View, 2022, 3, .	2.7	8
774	Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine. Viruses, 2022, 14, 540.	1.5	6
775	Postvaccination SARS-CoV-2 Infections among Healthcare Professionals: A Real World Evidence Study. Vaccines, 2022, 10, 511.	2.1	1
776	Various vaccine platforms in the field of COVID-19. Beni-Suef University Journal of Basic and Applied Sciences, 2022, 11, 35.	0.8	10
777	The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity. Journal of the American Chemical Society, 2022, 144, 4746-4753.	6.6	43
778	RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein. Biomicrofluidics, 2022, 16, 024105.	1.2	2
779	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. Pathogens, 2022, 11, 368.	1.2	23
780	Therapeutically harnessing extracellular vesicles. Nature Reviews Drug Discovery, 2022, 21, 379-399.	21.5	263

#	Article	IF	Citations
781	Pandemic-response adenoviral vector and RNA vaccine manufacturing. Npj Vaccines, 2022, 7, 29.	2.9	12
782	Large-scale design and refinement of stable proteins using sequence-only models. PLoS ONE, 2022, 17, e0265020.	1.1	17
783	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. Drug Design, Development and Therapy, 2022, Volume 16, 951-972.	2.0	4
784	The Fundamental Flaws of the CNBSS Trials: A Scientific Review. Journal of Breast Imaging, 2022, 4, 108-119.	0.5	11
785	Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2. Vaccines, 2022, 10, 516.	2.1	2
786	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. Journal of Personalized Medicine, 2022, 12, 386.	1.1	5
787	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. Journal of Headache and Pain, 2022, 23, 41.	2.5	43
788	CHARM: COVID-19 Health Action Response for Marinesâ€“Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test. PLoS ONE, 2022, 17, e0266691.	1.1	1
789	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. Brazilian Journal of Microbiology, 2022, 53, 1133-1157.	0.8	22
790	Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis. Biomedicines, 2022, 10, 834.	1.4	16
791	Evaluating Pharmacistsâ€™ Pharmacological Knowledge and Views Regarding Pfizer-BioNTech COVID-19 Vaccine in Saudi Arabia. Clinical Pharmacology: Advances and Applications, 2022, Volume 14, 27-35.	0.8	1
792	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. EBioMedicine, 2022, 78, 103962.	2.7	8
793	Effectiveness, Adverse Events, and Immune Response Following Double Vaccination with BNT162b2 in Staff at the National Comprehensive Cancer Center (NCCC). Vaccines, 2022, 10, 558.	2.1	2
794	Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. BMJ Open, 2022, 12, e056872.	0.8	12
795	A global survey in the developmental landscape of possible vaccination strategies for COVID-19. Clinical Immunology, 2022, 237, 108958.	1.4	11
796	Acceptance, effects, and tolerability in the vaccination process against SARS-CoV-2 virus among cancer patients in Bosnia and Herzegovina: a single-center cross-sectional study. Bosnian Journal of Basic Medical Sciences, 2022, , .	0.6	1
797	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 â€“ a review. Translational Research, 2022, 242, 1-19.	2.2	3
798	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Microbiological Research, 2022, 258, 126993.	2.5	22

#	Article	IF	Citations
799	mRNA vaccines for COVID-19 and diverse diseases. Journal of Controlled Release, 2022, 345, 314-333.	4.8	50
800	Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE). Clinical Immunology Communications, 2022, 2, 54-56.	0.5	2
801	Spatial-Temporal Data Science of COVID-19 Data. , 2021, , .		9
802	mRNAç––æ³•çš„ç”©¶è¿›å±•ä¸Žæ€ç˜. Scientia Sinica Vitae, 2023, 53, 30-49.	0.1	1
803	Zwitterionic Phospholipidation of Cationic Polymers Facilitates Systemic mRNA Delivery to Spleen and Lymph Nodes. Journal of the American Chemical Society, 2021, 143, 21321-21330.	6.6	66
805	mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship. Vaccines, 2021, 9, 1503.	2.1	23
806	Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. GeroScience, 2022, 44, 57-61.	2.1	3
807	SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. Npj Vaccines, 2021, 6, 151.	2.9	36
808	Building a community to engineer synthetic cells and organelles from the bottom-up. ELife, 2021, 10, .	2.8	27
809	Immunization against severe acute respiratory syndrome Coronavirus 2: an overview. African Health Sciences, 2021, 21, 1574-83.	0.3	2
810	Distinguishing Features Common to Dual Fatal Herpes Simplex Virus Infections That Occur in Both a Pregnant Woman and Her Newborn Infant. Viruses, 2021, 13, 2542.	1.5	4
811	A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern. Frontiers in Immunology, 2021, 12, 765211.	2.2	16
813	Delayed-type hypersensitivity reactions to Pfizer BioNTech SARS-CoV-2 vaccine. Postgraduate Medical Journal, 2022, 98, 658-659.	0.9	1
814	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. 3 Biotech, 2022, 12, 15.	1.1	20
815	The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. Infection and Drug Resistance, 2021, Volume 14, 5271-5285.	1.1	16
816	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nature Communications, 2021, 12, 7105.	5.8	22
817	Advances in the design and development of SARS-CoV-2 vaccines. Military Medical Research, 2021, 8, 67.	1.9	26
819	Nanoscience versus Viruses: The SARSâ€CoVâ€2 Case. Advanced Functional Materials, 2022, 32, 2107826.	7.8	8

#	Article	IF	Citations
820	COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. Vaccines, 2022, 10, 37.	2.1	15
821	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. Journal of Microbiology and Biotechnology, 2021, 31, 1601-1614.	0.9	8
824	Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. Methods in Molecular Biology, 2022, 2410, 229-263.	0.4	1
825	Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RÎ³cKO.NOD) for COVID-19. Human Vaccines and Immunotherapeutics, 2022, 18, 1-16.	1.4	6
826	BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19. Frontiers in Immunology, 2022, 13, 797918.	2.2	1
827	Nano toolbox in immune modulation and nanovaccines. Trends in Biotechnology, 2022, 40, 1195-1212.	4.9	31
828	TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer. Nature Communications, 2022, 13, 2165.	5.8	43
829	Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	1.4	14
830	Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems. Pharmaceutics, 2022, 14, 856.	2.0	4
831	COVID-19 Vaccines: Current and Future Perspectives. Vaccines, 2022, 10, 608.	2.1	26
832	Isotope Labels Combined with Solution NMR Spectroscopy Make Visible the Invisible Conformations of Small-to-Large RNAs. Chemical Reviews, 2022, 122, 9357-9394.	23.0	12
833	Chemo-Enzymatic Modification of the 5â€² Cap To Study mRNAs. Accounts of Chemical Research, 2022, 55, 1249-1261.	7.6	13
834	The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study. Biomedicines, 2022, 10, 911.	1.4	9
835	RNA therapy: rich history, various applications and unlimited future prospects. Experimental and Molecular Medicine, 2022, 54, 455-465.	3.2	92
837	Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food and Chemical Toxicology, 2022, 164, 113008.	1.8	70
838	Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy, 2022, 7, 94.	7.1	177
839	Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis. Cell Journal, 2021, 23, 523-531.	0.2	4
840	Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, E. coli Ribonuclease I and Human RNase A. Frontiers in Microbiology, 2021, 12, 660149.	1.5	1

#	Article	IF	Citations
841	Ethical Issues involving the development of Covid-19 vaccines: Role of vaccine development, clinical trials and speed of peer review in dissuading public vaccine hesitancy. Ethics in Biology, Engineering & Medicine, 2022, , .	0.1	0
842	Acceptance or Rejection of the COVID-19 Vaccine: A Study on Iranian Peopleâ€™s Opinions toward the COVID-19 Vaccine. Vaccines, 2022, 10, 670.	2.1	8
843	Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2201433119.	3.3	19
844	2â€²- and 3â€²-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2. Journal of Physical Chemistry Letters, 2022, 13, 4111-4118.	2.1	11
845	Recent developments in SARSâ€CoVâ€2 vaccines: A systematic review of the current studies. Reviews in Medical Virology, 2023, 33, e2359.	3.9	17
846	Polygoni multiflori radix extracts inhibit SARS-CoV-2 pseudovirus entry in HEK293T cells and zebrafish larvae. Phytomedicine, 2022, 102, 154154.	2.3	6
847	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. Cureus, 2022, , .	0.2	3
848	TNF-Î±+ CD4+ TÂcells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Reports Medicine, 2022, 3, 100640.	3.3	15
849	Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles. Human Gene Therapy, 2022, 33, 782-788.	1.4	6
850	Efficacy of COVID-19 vaccines by race and ethnicity. Public Health, 2022, , .	1.4	6
851	Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAEâ€”An Observational Study. Frontiers in Public Health, 2022, 10, .	1.3	50
852	Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review. Cureus, 2022, , .	0.2	3
853	The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology, 2022, 40, 840-854.	9.4	248
854	Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population. Npj Vaccines, 2022, 7, 52.	2.9	9
855	SARS-CoV-2: overview of immune response, insights into vaccine platforms and their challenges. Exploration of Immunology, 0, , 245-263.	1.7	0
856	ReactivaciÃ³n del virus varicela zÃ³ster tras vacunaciÃ³n contra la covid 19. Piel, 2022, , .	0.0	0
857	Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy. Computational and Structural Biotechnology Journal, 2022, 20, 2442-2454.	1.9	13
858	Demographic and Clinical Factors Associated With Antiâ€“SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses. JAMA Network Open, 2022, 5, e2212996.	2.8	9

#	Article	IF	Citations
859	EVALUATION OF COVID-19 VACCINES EFFICACY IN IRAQI PEOPLES. WiadomoÅ›ci Lekarskie, 2022, 75, 929-937.	0.1	1
861	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. Pharmaceutics, 2022, 14, 1101.	2.0	15
862	mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	160
863	A review on risk assessment of formulation development and technology transfer of COVID-19 vaccines. Vitae, 2022, 29, .	0.2	0
865	Protective neutralizing epitopes in SARSâ€CoVâ€2. Immunological Reviews, 2022, 310, 76-92.	2.8	23
866	Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers. Seminars in Cancer Biology, 2022, 86, 358-375.	4.3	17
867	SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study. BMJ Open, 2022, 12, e052130.	0.8	2
869	Paving the Way Towards Precision Vaccinology: The Paradigm of Myocarditis After Coronavirus Disease 2019 (COVID-19) Vaccination. Clinical Infectious Diseases, 2022, 75, S18-S23.	2.9	2
870	Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate. Vaccines, 2022, 10, 897.	2.1	5
871	Knowledge, attitudes, and practices of pregnant women regarding COVIDâ€19 vaccination in pregnancy in 7 lowâ€and middleâ€income countries: An observational trial from the Global Network for Women and Childrenâ€™s Health Research. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 2002-2009.	1.1	17
872	mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Frontiers in Immunology, 2022, 13, .	2.2	34
873	Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer, 2022, 172, 41-50.	1.3	6
874	Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine. Journal of Immunological Methods, 2022, 506, 113293.	0.6	4
875	Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. International Immunopharmacology, 2022, 109, 108906.	1.7	43
877	Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models. Molecular Immunology, 2022, 149, 107-118.	1.0	2
878	Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination. Future Oncology, 2022, 18, 2537-2550.	1.1	4
880	Reply to â€˜Development of severe pemphigus vulgaris following <scp>SARSâ€CoV</scp>â€2 vaccination with <scp>BNT162b2</scp>â€™ by Solimani etâ€‰al.. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	25
881	Rapid and Low-Cost Detection and Quantification of SARS-CoV-2 Antibody Titers of ICU Patients with Respiratory Deterioration Using a Handheld Thermo-Photonic Device. Biomedicines, 2022, 10, 1424.	1.4	2

#	Article	IF	Citations
882	Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. Frontiers in Medicine, 0, 9, .	1.2	0
883	High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium. Viruses, 2022, 14, 1257.	1.5	7
884	The Past, Present, and Future of Non-Viral CAR T Cells. Frontiers in Immunology, 0, 13, .	2.2	39
885	Addressing COVID-19 vaccine hesitancy. Drugs in Context, 0, 11, 1-19.	1.0	11
886	Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signals. Sleep Medicine, 2022, 98, 79-86.	0.8	6
887	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nature Communications, 2022, 13, .	5.8	63
888	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. Vaccine, 2022, 40, 4220-4230.	1.7	27
889	Systematic Modulation of the Lipid Composition Enables to Tune Liposome Cellular Uptake Pathways. SSRN Electronic Journal, 0, , .	0.4	0
890	mRNA delivery technologies: Toward clinical translation. International Review of Cell and Molecular Biology, 2022, , 207-293.	1.6	5
892	Macroscopic charge segregation in driven polyelectrolyte solutions. Soft Matter, 0, , .	1.2	1
893	COVID-19 WAR: Controversial Guidelines. Journal of Internal Medicine and Emergency Research, 0, , .	0.0	0
894	The potential of developing a protective peptideâ€based vaccines against SARSâ€CoVâ€2. Drug Development Research, 0, , .	1.4	2
895	Comparison of COVID-19 Vaccines Introduced in Korea. Biomedical Science Letters, 2022, 28, 67-82.	0.0	1
896	Mortality and risk factors for COVID-19 in hemodialysis patients: A systematic review and meta-analysis. Science Progress, 2022, 105, 003685042211108.	1.0	12
897	mRNA vaccines: Past, present, future. Asian Journal of Pharmaceutical Sciences, 2022, 17, 491-522.	4.3	24
898	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. Advances in Therapy, 2022, 39, 3789-3798.	1.3	3
899	Type I Interferons Promote Germinal Centers Through B Cell Intrinsic Signaling and Dendritic Cell Dependent Th1 and Tfh Cell Lineages. Frontiers in Immunology, 0, 13, .	2.2	9
900	Measurement of anti SARS-CoV-2 RBD IgG in saliva: validation of a highly sensitive assay and effects of the sampling collection method and correction by protein. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1683-1689.	1.4	3

#	Article	IF	Citations
901	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. Scientific Reports, 2022, 12, .	1.6	23
902	Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. Vaccines, 2022, 10, 1068.	2.1	9
903	Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2. Journal of Molecular Cell Biology, 2022, 14, .	1.5	2
904	Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective. Journal of Infectious Diseases, 0, , .	1.9	8
905	Antibody-Based Approaches to Target Pancreatic Tumours. Antibodies, 2022, 11, 47.	1.2	7
906	Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerging Microbes and Infections, 2022, 11, 1828-1832.	3.0	32
907	Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant. Frontiers in Immunology, 0, 13, .	2.2	8
908	Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nature Biomedical Engineering, 2022, 6, 791-805.	11.6	100
909	A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antiviral Research, 2022, 204, 105370.	1.9	16
910	Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19. IScience, 2022, 25, 104719.	1.9	0
911	Why does COVID-19 continue to spread despite mass vaccination?. Frontiers in Public Health, 0, 10, .	1.3	2
912	Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: Interaction between host immune responses and pathogen evasion. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	9
913	NMR spectroscopy spotlighting immunogenicity induced by COVID-19 vaccination to mitigate future health concerns. Current Research in Immunology, 2022, 3, 199-214.	1.2	1
914	Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria. Viruses, 2022, 14, 1642.	1.5	4
915	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. International Journal of Molecular Sciences, 2022, 23, 8485.	1.8	6
916	Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. Frontiers in Immunology, 0, 13, .	2.2	10
919	Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. Vaccine, 2022, 40, 5701-5708.	1.7	0
920	Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nature Medicine, 2022, 28, 1619-1629.	15.2	56

#	Article	IF	Citations
921	Current Vaccine Platforms in Enhancing T-Cell Response. Vaccines, 2022, 10, 1367.	2.1	8
922	A case for conducting business-to-business experiments with multi-arm multi-stage adaptive designs. Journal of Marketing Analytics, 0, , .	2.2	0
923	Vaccines platforms and COVID-19: what you need to know. Tropical Diseases, Travel Medicine and Vaccines, 2022, 8, .	0.9	16
925	Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers. Vaccine, 2022, 40, 5445-5451.	1.7	3
926	The effect of <scp>BNT</scp>162b2 <scp>SARSâ€C</scp>o<scp>V</scp>â€2 m<scp>RNA</scp> vaccine on menstrual cycle symptoms in healthy women. International Journal of Gynecology and Obstetrics, 2023, 160, 313-318.	1.0	9
927	Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan. Journal of the Formosan Medical Association, 2023, 122, 78-81.	0.8	1
928	Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross- sectional survey in Northwest Ethiopia. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	3
929	Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. Frontiers in Immunology, 0, 13, .	2.2	13
930	Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of Mycobacterium tuberculosis. Molecular Diversity, 2023, 27, 1613-1632.	2.1	4
931	Emerging trends of research on mRNA vaccines: A co-citation analysis. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
933	Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. Med, 2022, 3, 760-773.e5.	2.2	13
934	Effective gene therapy of Stargardt disease with PEG-ECO/pGRK1-ABCA4-S/MAR nanoparticles. Molecular Therapy - Nucleic Acids, 2022, 29, 823-835.	2.3	13
935	Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine. Frontiers in Immunology, 0, 13, .	2.2	2
936	Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients. Frontiers in Medicine, 0, 9, .	1.2	2
937	Nutrition as Personalized Medicine against SARS-CoV-2 Infections: Clinical and Oncological Options with a Specific Female Groups Overview. International Journal of Molecular Sciences, 2022, 23, 9136.	1.8	17
938	Recent advances in the vaccine development for the prophylaxis of SARS Covid-19. International Immunopharmacology, 2022, 111, 109175.	1.7	5
939	A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nature Communications, 2022, 13, .	5.8	51
940	Evaluation of Short-Term Symptoms Associated With COVID-19 Vaccines Used Among Adolescents in Saudi Arabia. Cureus, 2022, , .	0.2	0

#	Article	IF	Citations
941	Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	7
942	A BRIEF DESCRIPTION OF COVID-19 PULMONARY VIRAL INFECTION AND REPURPOSING OF DRUGS FOR ITS TREATMENT. International Journal of Applied Pharmaceutics, 0, , 22-31.	0.3	1
943	Hazards of vaccinating the way out of Covid-19 pandemic: Study of adverse events following immunization (Aefi) in India. Medical Journal of Dr D Y Patil Vidyapeeth, 2022, .	0.0	0
944	COVID-19 Vaccination-Induced Ventricular Fibrillation in an Afebrile Patient With Brugada Syndrome. Journal of Korean Medical Science, 2022, 37, .	1.1	4
945	Acceptance of covid-19 vaccine among the healthcare providers in India. Journal of Family Medicine and Primary Care, 2022, 11, 3465.	0.3	0
946	Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults. Infection and Chemotherapy, 2022, 54, 504.	1.0	2
947	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	1.1	12
948	SARS-COV-2 and Other mRNA Vaccines. RNA Technologies, 2022, , 113-138.	0.2	0
949	A review on COVID-19 vaccinations. Biomedical and Biotechnology Research Journal, 2022, 6, 50.	0.3	6
950	Antibody levels over time against the novel coronavirus and incidence of adverse reaction after vaccination. Health Evaluation and Promotion, 2022, 49, 462-469.	0.0	0
951	Nanotechnological Systems and Lung: A Perfect Combination for Lung Pharmaceutical Applications. Current Medicinal Chemistry, 2022, 29, .	1.2	1
952	Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study. Infection and Drug Resistance, 0, Volume 15, 4335-4346.	1.1	8
953	Psychological and situational factors associated with COVID-19 vaccine intention among postpartum women in Pakistan: a cross-sectional study. BMJ Open, 2022, 12, e063469.	0.8	2
954	Gravesâ€˜ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases. Frontiers in Endocrinology, 0, 13, .	1.5	11
955	Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?. International Journal of Molecular Sciences, 2022, 23, 10881.	1.8	23
956	Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2. Avicenna Journal of Medical Biotechnology, 0, , .	0.2	0
958	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. Nature Communications, 2022, 13, .	5.8	11
959	A randomized, doubleâ€blind, placeboâ€controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARSâ€CoVâ€2 vaccine SCoK in adults. Clinical and Translational Medicine, 2022, 12, .	1.7	3

#	Article	IF	Citations
960	Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
961	Long-Term Antibody Response to SARS-CoV-2 in Children. Journal of Clinical Immunology, 2023, 43, 46-56.	2.0	8
962	COVID-19 Vaccine in Inherited Metabolic Disorders Patients: A Cross-Sectional Study on Rate of Acceptance, Safety Profile and Effect on Disease. International Journal of Environmental Research and Public Health, 2022, 19, 12227.	1.2	1
963	Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis. Rheumatology, 2023, 62, 1445-1450.	0.9	9
964	COVID-19 and cellular senescence. Nature Reviews Immunology, 2023, 23, 251-263.	10.6	54
965	mRNA vaccines: A novel weapon to control infectious diseases. Frontiers in Microbiology, 0, 13, .	1.5	10
966	Atropine-functionalized gold nanoparticles binding to muscarinic receptors after passage across the intestinal epithelium. Royal Society Open Science, 2022, 9, .	1.1	1
967	Isolated popliteal artery lesion due to giant cell vasculitis post COVID-19 mRNA vaccine and COVID-19 asymptomatic infection. Vascular, 2024, 32, 226-230.	0.4	3
969	Medicine, 2021, 110, 2099-2103.	0.0	0
970	Recombinant Vaccines: The Revolution Ahead. , 2022, , 163-200.		0
971	Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein. Journal of Microbiology and Biotechnology, 2022, 32, 1335-1343.	0.9	2
973	Electroporation in Clinical Applicationsâ€"The Potential of Gene Electrotransfer and Electrochemotherapy. Applied Sciences (Switzerland), 2022, 12, 10821.	1.3	5
974	Efficacy and safety of four COVID-19 vaccines in preventing SARS-CoV-2 infection: A rapid review. Biomedica, 2022, 42, 19-31.	0.3	2
975	SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders. Applied Biochemistry and Biotechnology, 2023, 195, 1541-1573.	1.4	4
976	Genetically modified organisms: adapting regulatory frameworks for evolving genome editing technologies. Biological Research, 2022, 55, .	1.5	10
977	An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. Journal of Nanobiotechnology, 2022, 20, .	4.2	38
978	Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity. Vaccines, 2022, 10, 1708.	2.1	3
980	Multiple Evanescent White Dot Syndrome Following COVID-19 mRNA Vaccination. Ocular Immunology and Inflammation, 2023, 31, 1240-1244.	1.0	5

#	Article	IF	Citations
981	Fear of COVID-19 and Vaccine Hesitancy among Pregnant Women in Poland: A Cross-Sectional Study. Vaccines, 2022, 10, 1700.	2.1	7
982	Evaluation of hematological abnormalities in subjects vaccinated with BNT162b2 in a longitudinal cohort of the CORE study. Rivista Italiana Della Medicina Di Laboratorio, 0, , .	0.2	0
983	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	2.3	3
984	Drug-induced liver injury after covid-19 mRNA vaccine: case report. Colombia Medica, 2022, 53, e5015187.	0.7	2
985	Acute panuveitis after COVID-19 mRNA booster vaccination following cataract surgery. American Journal of Ophthalmology Case Reports, 2022, 28, 101726.	0.4	2
986	Varicella zoster virus reactivation following COVIDâ€19 vaccination in patients with autoimmune inflammatory rheumatic diseases: A crossâ€sectional Chinese study of 318 cases. Journal of Medical Virology, 2023, 95, .	2.5	11
987	Effectiveness of COVID-19 vaccines in a large European hemodialysis cohort. , 0, 2, .		1
988	Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. Biomedicines, 2022, 10, 2892.	1.4	4
989	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. Expert Review of Vaccines, 2022, 21, 1739-1761.	2.0	2
990	Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. Vaccines, 2022, 10, 1931.	2.1	1
991	Highâ€“temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines. Science Advances, 2022, 8, .	4.7	7
992	Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS. Journal of Proteome Research, 0, , .	1.8	2
993	Capturing SARS-CoV-2 from patient samples with low viral abundance: a comparative analysis. Scientific Reports, 2022, 12, .	1.6	1
994	Vaccines on demand, part II: future reality. Expert Opinion on Drug Discovery, 2023, 18, 119-127.	2.5	3
995	Adverse events following administration of COVID-19 vaccines in Saudi Arabia. Scientific Reports, 2022, 12, .	1.6	7
996	Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. Clinics in Laboratory Medicine, 2022, 42, 687-704.	0.7	0
997	Ethnological aspects of COVID-19. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
998	Silica Nanoparticles with Virus-Mimetic Spikes Enable Efficient siRNA Delivery In Vitro and In Vivo. Research, 2022, 2022, .	2.8	5

#	Article	IF	Citations
999	Presentations at the UK National Immunisation Conference. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
1000	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. Frontiers in Immunology, 0, 13, .	2.2	3
1001	Immunogenicity of the Two mRNA SARS-CoV-2 Vaccines in a Large Cohort of Dialysis Patients. Infectious Disease Reports, 2022, 14, 946-954.	1.5	1
1002	Current state of, prospects for, and obstacles to mRNA vaccine development. Drug Discovery Today, 2023, 28, 103458.	3.2	5
1003	Lipid carriers for mRNA delivery. Acta Pharmaceutica Sinica B, 2023, 13, 4105-4126.	5.7	13
1004	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	1.7	2
1005	COVID-19 Vaccination Is Associated with a Better Outcome in Acute Ischemic Stroke Patients: A Retrospective Observational Study. Journal of Clinical Medicine, 2022, 11, 6878.	1.0	3
1006	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
1007	Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign. European Journal of General Practice, 2023, 29, .	0.9	2
1008	Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV. Frontiers in Immunology, 0, 13, .	2.2	10
1009	Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nature Medicine, 2023, 29, 344-347.	15.2	249
1010	Biomimetic cell-derived nanocarriers in cancer research. Journal of Nanobiotechnology, 2022, 20, .	4.2	19
1011	Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview. Virology Journal, 2022, 19, .	1.4	14
1012	Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. PLOS Global Public Health, 2022, 2, e0001308.	0.5	2
1013	Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. Expert Review of Vaccines, 2023, 22, 35-53.	2.0	8
1014	COVID-19 vaccination and liver disease. World Journal of Gastroenterology, 0, 28, 6791-6810.	1.4	6
1015	Efficacy and safety of COVID-19 vaccines. The Cochrane Library, 2023, 2023, .	1.5	60
1016	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. Scientific Reports, 2022, 12, .	1.6	20

#	Article	IF	Citations
1017	A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. Npj Vaccines, 2022, 7, .	2.9	20
1018	5â€Ethynyluridine: A Bioâ€orthogonal Uridine Variant for mRNAâ€Based Therapies and Vaccines. ChemBioChem, 2023, 24, .	1.3	0
1019	The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19. Journal of Inflammation Research, 0, Volume 16, 145-160.	1.6	5
1020	Engineer RNAâ€Protein Nanowires as Lightâ€Responsive Biomaterials. Small, 2023, 19, .	5.2	2
1021	Atomistic Insights into Organization of RNA-Loaded Lipid Nanoparticles. Journal of Physical Chemistry B, 2023, 127, 1158-1166.	1.2	4
1022	The impact of COVID-19 on kidney transplant care. Frontiers in Medicine, 0, 9, .	1.2	1
1023	An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis. Vaccines, 2023, 11, 130.	2.1	12
1024	Drug-induced sarcoidosis-like reaction three months after BNT162b2 mRNA COVID-19 vaccination: A case report and review of literature. World Journal of Clinical Cases, 0, 11, 177-186.	0.3	1
1025	Bioinspired Lipid Nanocarriers for RNA Delivery. ACS Bio & Med Chem Au, 2023, 3, 114-136.	1.7	8
1026	COVID-19 outbreak after 100 days without community transmission: Epidemiological analysis of factors associated with death. Heliyon, 2023, 9, e12941.	1.4	0
1028	Systematic modulation of the lipid composition enables the tuning of liposome cellular uptake. Acta Biomaterialia, 2023, 158, 463-474.	4.1	5
1029	Other Facets of SARS-CoV-2 Immunity, the Risk of Immune Tolerance and T Cell Exhaustion. , 2023, , 325-363.		0
1030	Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE). BMJ Open, 2022, 12, e069065.	0.8	5
1031	An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. Vaccines, 2023, 11, 51.	2.1	9
1032	An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV. Virologica Sinica, 2023, 38, 244-256.	1.2	3
1033	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. Biology, 2023, 12, 177.	1.3	11
1034	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Frontiers in Immunology, 0, 14, .	2.2	14
1035	Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India. Journal of Multidisciplinary Healthcare, 0, Volume 16, 161-174.	1.1	6

#	Article	IF	Citations
1036	Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. American Journal of Gastroenterology, 2023, 118, 1388-1394.	0.2	3
1037	Positiveâ€strand RNA virusesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2023, 1521, 46-66.	1.8	0
1038	Unravelling the role of individual components in pBAE/polynucleotide polyplexes in the synthesis of tailored carriers for specific applications: on the road to rational formulations. Nanoscale Advances, 2023, 5, 1611-1623.	2.2	4
1039	Efectos adversos a las vacunas contra la COVID-19 en Paraguay en el 2021. Revista CientÃfica Ciencias De La Salud, 0, 5, 01-08.	0.1	11
1040	COVID-19 Vaccination and Alcohol Consumption: Justification of Risks. Pathogens, 2023, 12, 163.	1.2	4
1041	Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. Pharmaceutics, 2023, 15, 451.	2.0	6
1042	Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. Oxford Open Immunology, 2023, 4, .	1.2	3
1043	Ionizable lipid nanoparticles deliver mRNA to pancreatic Î² cells via macrophage-mediated gene transfer. Science Advances, 2023, 9, .	4.7	35
1044	A Short Introduction to Vaccines. , 2023, , 1-32.		0
1045	Side Effects of COVID-19 Vaccines Among Diabetic Subjects and Healthy Individuals. Cureus, 2023, , .	0.2	5
1046	Dynamics of the Negative Discourse Toward COVID-19 Vaccines: Topic Modeling Study and an Annotated Data Set of Twitter Posts. Journal of Medical Internet Research, 0, 25, e41319.	2.1	7
1047	An in vitro lipid-mixing assay to investigate the fusion between small extracellular vesicles and endosome. Analytical Biochemistry, 2023, 669, 115130.	1.1	1
1048	Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infectious Diseases, 2023, 23, .	1.3	1
1049	Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine, 2023, 41, 1925-1933.	1.7	11
1050	Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency. Annals of Allergy, Asthma and Immunology, 2023, , .	0.5	0
1051	Versatile strategy using vaccinia virus-capping enzyme to synthesize functional 5â€² cap-modified mRNAs. Nucleic Acids Research, 2023, 51, e34-e34.	6.5	8
1053	Biological Controls and Standards for the Study and Control of Infectious Diseases. , 2023, , 21-34.		0
1054	Editorial: Innate immune responses to SARS-CoV-2 in infected and vaccinated individuals. Frontiers in Immunology, 0, 14, .	2.2	1

#	Article	IF	Citations
1055	Toxicological Assessments of a Pandemic COVID-19 Vaccineâ€"Demonstrating the Suitability of a Platform Approach for mRNA Vaccines. Vaccines, 2023, 11, 417.	2.1	5
1056	Investigation of Neurological Complications after COVID-19 Vaccination: Report of the Clinical Scenarios and Review of the Literature. Vaccines, 2023, 11, 425.	2.1	4
1057	Recent advances in nanocomposite-based delivery systems for targeted CRISPR/Cas delivery and therapeutic genetic manipulation. Journal of Materials Chemistry B, 2023, 11, 5251-5271.	2.9	5
1058	Immunogenicity of CRISPR therapeuticsâ€"Critical considerations for clinical translation. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	9
1059	Immunogenicity Assessment on Clinical Trials of SARS-CoV-2 Vaccines. Indonesian Journal of Clinical Pathology, 2022, 28, 202-208.	0.1	0
1060	Enhancing electroporation-induced liposomal drug release in suspension and solid phases. International Journal of Pharmaceutics, 2023, 635, 122744.	2.6	0
1061	Approved Nanomedicine against Diseases. Pharmaceutics, 2023, 15, 774.	2.0	14
1062	A mini review for lipid-based nanovaccines: from their design to their applications. Journal of Liposome Research, 2023, 33, 214-233.	1.5	1
1063	The comparison ofÂSARS-CoV-2 antibody levels in medical personnel induced by different types ofÂvaccines compared to theÂnatural infection. Central-European Journal of Immunology, 0, , .	0.4	1
1064	Effect of anxiety and depression on self-reported adverse reactions to COVID-19 vaccine: a cross-sectional study in Shanghai, China. BMC Public Health, 2023, 23, .	1.2	2
1065	Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models. International Journal of Molecular Sciences, 2023, 24, 5011.	1.8	1
1066	Our Approach in COVID-19 Measures. Health Evaluation and Promotion, 2022, 49, 645-649.	0.0	0
1067	Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines. International Journal of Environmental Research and Public Health, 2023, 20, 4796.	1.2	2
1068	A novel mAb broadly neutralizes SARSâ€CoVâ€2 VOCs in vitro and in vivo, including the Omicron variants. Journal of Medical Virology, 2023, 95, .	2.5	1
1069	COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review. Clinical Oncology, 2023, , .	0.6	2
1070	mRNA therapeutics: New vaccination and beyond. Fundamental Research, 2023, 3, 749-759.	1.6	6
1071	Longer intervals between SARSâ€CoVâ€2 infection and mRNAâ€1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 2023, 95, .	2.5	1
1072	Computational Prodrug Design Methodology for Liposome Formulability Enhancement of Small-Molecule APIs. Molecular Pharmaceutics, 2023, 20, 2119-2127.	2.3	7

#	Article	IF	Citations
1073	Supraventricular tachycardia and deep vein thrombosis following Moderna vaccination: A case series. Clinical Case Reports (discontinued), 2023, 11, .	0.2	0
1074	The interplay between hypovitaminosis D and the immune dysfunction in the arteriovenous thrombotic complications of the sever coronavirus disease 2019 (COVID-19) infection. Blood Coagulation and Fibrinolysis, 2023, 34, 129-137.	0.5	2
1076	Assessment Of Antibody Levels In A Population Vaccinated With Sputnik V. Russian Open Medical Journal, 2023, 12, .	0.1	0
1077	A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time. PLoS ONE, 2023, 18, e0283537.	1.1	3
1078	mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic. Frontiers in Immunology, 0, 14, .	2.2	3
1080	TREM2+ and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques. Nature Communications, 2023, 14, .	5.8	10
1081	A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response. Vaccines, 2023, 11, 832.	2.1	1
1082	Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines. Journal of Blood Medicine, 0, Volume 14, 295-302.	0.7	1
1083	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines, 2023, 11, 849.	2.1	12
1084	Ferrocenoyl-substituted quinolinone and coumarin as organometallic inhibitors of SARS-CoV-2 3CLpro main protease. Metallomics, 2023, 15, .	1.0	1
1085	Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimerâ€™s disease. Chemical Engineering Journal, 2023, 466, 143152.	6.6	4
1092	A profound perception into manifestation of lifesaver. AIP Conference Proceedings, 2023, , .	0.3	0
1098	Therapeutic Potential of Rhodium Complexes. Springer Briefs in Molecular Science, 2023, , 13-53.	0.1	0
1100	RNA Vaccines: The Evolution, Applications, and the Challenges Ahead. , 2023, , 349-364.		1
1113	Vaccine adjuvants: mechanisms and platforms. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	41
1116	A Short History of Vaccination. , 2023, , 1-16.e9.		0
1117	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
1128	mRNA vaccines in disease prevention and treatment. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	9

#	Article	IF	Citations
1153	RNA-based nanomedicines and their clinical applications. Nano Research, 0, , .	5.8	0
1166	Immunogenicity and Protective Efficacy of Nucleic Acid-Based Vaccines Against COVID-19: A Systematic Review. Molecular Biotechnology, 0, , .	1.3	0
1177	Overview of diagnostic tools and nano-based therapy of SARS-CoV-2 infection. Chemical Papers, 2024, 78, 2123-2154.	1.0	0
1181	Therapeutic landscape of SARS-CoV-2. , 2024, , 83-99.		0
1182	RNA therapeutics for regenerative medicine. Progress in Molecular Biology and Translational Science, 2024, , 163-176.	0.9	0
1186	Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants. Current Microbiology, 2024, 81, .	1.0	0